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One primary goal of analyzing genomic data is the identification of biomarkers which may be 
causative of, correlated with, or otherwise biologically relevant to disease phenotypes. In this 
work, I implement and extend a multivariate feature ranking algorithm called label propagation 
(LP) for biomarker discovery in genome-wide single-nucleotide polymorphism (SNP) data. This 
graph-based algorithm utilizes an iterative propagation method to efficiently compute the 
strength of association between a SNP and a phenotype. 
 I developed three extensions to the LP algorithm, with the goal of tailoring it to genomic 
data. The first extension is a modification to the LP score which yields a variable-level score for 
each SNP, rather than a score for each SNP genotype. The second extension incorporates prior 
biological knowledge that is encoded as a prior value for each SNP. The third extension enables 
the combination of rankings produced by LP and another feature ranking algorithm. 
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The LP algorithm, its extensions, and two control algorithms (chi squared and sparse 
logistic regression) were applied to 11 genomic datasets, including a synthetic dataset, a semi-
synthetic dataset, and nine genome-wide association study (GWAS) datasets covering eight 
diseases. The quality of each feature ranking algorithm was evaluated by using a subset of top-
ranked SNPs to construct a classifier, whose predictive power was evaluated in terms of the area 
under the Receiver Operating Characteristic curve. Top-ranked SNPs were also evaluated for 
prior evidence of being associated with disease using evidence from the literature. 
The LP algorithm was found to be effective at identifying predictive and biologically 
meaningful SNPs. The single-score extension performed significantly better than the original 
algorithm on the GWAS datasets. The prior knowledge extension did not improve on the feature 
ranking results, and in some cases it reduced the predictive power of top-ranked variants. The 
ranking combination method was effective for some pairs of algorithms, but not for others. 
Overall, this work’s main results are the formulation and evaluation of several algorithmic 
extensions of LP for use in the analysis of genomic data, as well as the identification of several 
disease-associated SNPs. 
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GLOSSARY 
Attribute – also called a dimension, feature, or variable, it represents a measured quality of the 
data  
Biomarker – any biochemical signal in the body which can be quantified 
Dimensionality reduction – any method which reduces the number of variables in a dataset 
Feature selection – any dimensionality reduction method which keeps original dimensions 
intact 
Feature ranking – any feature selection method which orders variables from most to least 
important 
Feature subset selection – any feature selection method which outputs a set of relevant features, 
while discarding the others 
GERP – genomic evolutionary rate profiling, a measure of SNP conservation 
kNN – k-nearest neighbor classifier 
LP – label propagation 
LP1 – single-score LP algorithm extension  
LP3 – original allele-scoring LP algorithm 
MAF – minor allele frequency 
Sample – a single data point composed of many attributes 
SLR – sparse logistic regression 
 xv 
SNV – single nucleotide variant 
SNP – single nucleotide polymorphism; a SNP is a common SNV (>5% MAF) 
SWRF – sigmoid weighted ReliefF
 xvi 
1.0  INTRODUCTION 
In today’s genomic era, DNA sequencing technology has become so inexpensive that it is readily 
available to everyday healthcare consumers. Genomic data has the potential to impact the way 
that healthcare providers prevent, diagnose, treat, and monitor disease. In the future, personalized 
medicine will enable physicians to generate a precise individualized assessment of risk of 
developing disease, and to pursue individualized therapy based on variations that are present in 
the individual’s genome. In order to achieve this goal of precision medicine, it is necessary to 
find useful and predictive biomarkers in high-dimensional genomic data. These data require 
sophisticated algorithms to analyze, because there are millions of variants measured for only a 
few thousand individuals. Given the comparative paucity of samples compared to the number of 
genomic loci that are measured, the challenge is to find the relatively few variants that are 
associated with disease. In this proposal I investigate the application of a graphical algorithm 
called label propagation (LP) for feature selection in genomic variant data. I also develop several 
novel extensions to the algorithm, tailoring it specifically to genomic variant data. In particular, I 
apply and evaluate the algorithm and its extensions on genome-wide single nucleotide 
polymorphism (SNP) data. 
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1.1 DIMENSIONALITY REDUCTION 
Dimensionality reduction (DR) techniques comprise a class of algorithms which are particularly 
applicable to the biomedical domain. Many forms of biomedical data, including genomic 
sequences, gene expression data, mass spectrometry data, or electronic health records, by their 
nature consist of a large number of variables. DR techniques either combine features to construct 
a smaller number of new features (feature construction), or select a subset of features that capture 
the important patterns in the data (feature selection). In the context of genomic analysis, DR 
techniques are often used to identify variants that are predictive of the disease or phenotype of 
interest. 
Many DR techniques have been applied to genomic data with the goals of biomarker 
discovery, identifying features which may be used for prediction. DR techniques are directly 
applicable for biomarker discovery, identifying disease-associated (and potentially causal) 
variants that can illuminate the genetic underpinnings of disease. Moreover, the selected variants 
can be used in developing predictive models, which utilize discriminative variants to predict a 
disease or phenotype from genomic data. No one DR technique is best across all domains, so it is 
imperative to find algorithms that are well-suited to the genomic domain. 
1.2 OVERVIEW OF LABEL PROPAGATION 
Label propagation (LP) is a multivariate, semi-supervised, graphical algorithm that has been 
applied for classification and ranking of features in a variety of domains. In the context of 
biomarker discovery, label propagation represents genomic data as a bipartite network where 
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genomic variants are represented by one set of nodes, and individuals with their disease status 
(case or control) are denoted by a second set of nodes. Links are allowed only between a variant 
node and a sample node, indicating which individuals exhibit which variants. LP labels the 
sample nodes with case or control status and propagates this information according to network 
topology.  Ultimately, features are scored according to their association with the case or control 
group. This scoring is a multivariate optimization of a particular cost criterion which attempts to 
balance the strength of the initial labeling with the strength of network diffusion. In addition to 
evaluating LP on genomic data for ranking variants associated with case or control status, I have 
further extended it for application to genomic data. 
1.3 HYPOTHESIS AND SPECIFIC AIMS 
I hypothesize that a semi-supervised LP method can be improved for feature ranking (and 
selection) in genomic data, and that its application to high-dimensional SNP data will yield better 
results than currently used feature selection methods in terms of both predictive performance and 
biological function. To test this hypothesis, I propose the following specific aims: 
 
Specific Aim 1. Extend the LP algorithm for SNP data to i) produce a probabilistic, single-SNP 
score rather than the current SNP-state score, ii) incorporate knowledge about the genome as 
priors, and iii) combine the single score LP method’s output with another feature ranking 
method’s output. 
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Specific Aim 2. Evaluate the LP extensions in Aim 1 on synthetic, semi-synthetic, and real 
GWAS datasets and compare its performance to that of chi square (univariate feature selection 
method), Relief, and Sparse Logistic Regression (multivariate feature selection methods). 
 
The two main aims are to develop several extensions to the LP algorithm, and to evaluate 
these extensions on a variety of data. 
1.4 CONTRIBUTIONS 
The goal of this work was to develop an effective computational method for feature selection in 
high-dimensional genomic data. From a machine learning standpoint, the algorithmic extensions 
to LP provide improvements to an already effective, efficient, multivariate feature ranking 
method. The LP extensions that I have developed are applicable to many other types of high-
dimensional data, and the combination method can enable the combination of existing effective 
algorithms. 
From a biomedical standpoint, the methods described in this work can be applied to 
genomic data to discover new variants that are associated with disease. Moreover, since LP is 
multivariate it can be applied to discover not only variants with main effects but also interacting 
genomic variants. In this dissertation, LP and its extensions were characterized and extensively 
evaluated using synthetic, semi-synthetic, and GWAS data 
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1.5 OVERVIEW OF DISSERTATION 
Chapter 2 provides relevant background to set the context for biomarker discovery in genomic 
data and surveys the related work in machine learning and genomic analysis. Chapter 3 describes 
the LP algorithm in detail, including previous LP variants and their applications in the literature. 
The novel extensions to LP are also described in this chapter. Chapter 4 describes the 
experimental method applied, including the performance metrics used to evaluate each 
algorithm, and a description of each dataset analyzed. Chapter 5 provides the results of the 
feature ranking experiments, and Chapter 6 summarizes the discoveries and conclusions drawn 
from this work. Full tables of results from all experiments are given in Appendix A and 
Appendix B. 
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2.0  BACKGROUND 
This chapter describes relevant background in the biomedical and machine learning domains. I 
present the overall problem of biomarker feature selection in high-dimensional genomic data, 
and review some of the methods that have been applied successfully as described in the 
literature. Section 2.1 describes how genetic variation can impact disease risk, and Section 2.2 
describes several types of variation commonly analyzed. Section 2.3 explains methods of 
discovering disease-associated SNPs. Section 2.4 covers some of the challenges encountered 
when performing large-scale genomic analysis. Section 2.5 gives an overview of dimensionality 
reduction methods, while Section 2.6 describes some particular DR methods in greater detail. 
2.1 GENETIC BASIS OF COMPLEX DISEASES 
Genetic inheritance has been understood for centuries as traits that are passed down from 
generation to generation. Genetics influences readily apparent traits such as hair, skin, or eye 
color, height, and several other physical attributes. Other genetic traits include susceptibility to 
many diseases, some of which are well-understood, and others whose genetic components are 
only just being unraveled. 
 Mendelian diseases are the simplest class of genetic diseases, directly caused by a 
variation at a single locus or gene. Presence of the genetic variant indicates presence of the 
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disease with high probability. Examples of Mendelian diseases are cystic fibrosis, which results 
from mutation in the CFTR gene, and Tay-Sach’s disease, which is caused by mutations in the 
HEXA gene. The genetics of many Mendelian diseases are relatively well understood; however, 
Mendelian diseases tend to be rare, recessive disorders that affect only a small portion of the 
population [1]. 
Common diseases such as late-onset Alzheimer’s disease or coronary artery disease stand 
in contrast to Mendelian diseases in that their prevalence is much higher in the population, and 
that their genetic component is more complex and less well-characterized. The genetic basis of 
common diseases does not lie in a single locus or gene, but is instead hypothesized to be the 
result of many variants working together. Dozens of genetic variants have been shown to be 
associated with many common diseases, including diabetes, bipolar disorder, and hypertension. 
A number of genetic models have been proposed to explain the genetic basis of common 
diseases. One prevalent hypothesis is the “common disease – common variant” hypothesis, 
which states that many common variants in combination determine risk of common diseases. 
This is supported by the observation that in several genome-wide association studies, results hold 
true across distinct populations with varying allele frequencies. If rare variants were responsible, 
varying allele frequencies would result in widely varying associations between different 
populations [2, 3]. 
In contrast to this hypothesis is the “common disease – rare variant” hypothesis, which 
states that rare variants rather than common ones that underlie common diseases. In support of 
this hypothesis, allele rarity has been shown to be proportional to the likelihood of disease 
association [4]. Intuitively, this is a result of selective pressure selecting against the deleterious 
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alleles, and it has been shown that particularly deleterious alleles are indeed rare in the 
population. 
It is likely that both common variants and rare variants are involved in common diseases 
and a combination of rare and common variants may be responsible for most common diseases. 
Thus, feature selection methods that are developed for genomic data should be able to identify 
both rare and common variants. 
2.2 GENETIC VARIATIONS 
The human genomic sequence consists of approximately 3 billion nucleotide pairs. Because the 
vast majority of the genomic sequence is identical across all humans, it is sufficient to focus 
analysis only on the variant regions of the sequence when analyzing genomic data in the context 
of disease. 
The commonest sequence variation is the single nucleotide variant (SNV) which is a 
variation that occurs when a single nucleotide (A, T, C, or G) at a specific location in the genome 
(called a locus) differs between individuals in a population. On a particular chromosome, a SNV 
can be one of two nucleotide pairs (A-T or C-G). These states are called alleles, the more 
common of which is called the major allele “A” (not to be confused with the specific nucleotide 
A) and the less frequent one is called minor allele “a”. Because humans have two versions of 
each chromosome (one from the mother and one from the father), the genotype is defined as the 
combination of the SNV alleles on both chromosomes. As such, there are three possible 
genotype states for each SNV – the major homozygous (AA), the heterozygous (Aa), and the 
minor homozygous (aa). 
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SNVs can be broadly grouped into common SNVs and rare SNVs. When the minor allele 
frequency (MAF) is 5% or higher in the population, a SNV is considered to be a common SNV 
[5], also called a single nucleotide polymorphism (SNP). Among the approximately 3 billion 
nucleotides in the human genome, tens of millions are common SNPs. In contrast, when the 
MAF is less than 5%, the SNV is considered to be a rare SNV. These uncommon SNVs account 
for very rare population-wide alleles, as well as loci of unexpected variation such as an 
individual’s unique random mutation in a particular locus. 
There are a variety of technologies for measuring SNPs. Several companies such as 
Illumina and Affymetrix offer low-cost SNP arrays which can genotype an individual at millions 
of SNPs at once. This is only a small subset of all SNPs in the genome, so SNP arrays often 
oversample non-synonymous SNPs (which alter the amino acid chain produced) and exonic 
SNPs (which are within protein-coding regions) in order to find biologically interesting variants. 
SNP arrays target loci of common variation because the genome is queried at particular sites, 
rather than being read as a string of nucleotides – to be cost-effective, coverage is not focused on 
loci where variation is not expected or extremely rare. 
Exome sequencing is a more recent technology used for measuring the genome. This 
method reads all nucleotide pairs in the exome, which is the protein coding portion of the 
genome, consisting of only about 1.5% of the full genome. This method can discover very rare, 
even unique mutations in the DNA sequence, because it does not just query loci of expected 
variation. Furthermore, variation within genes may be easier to understand than intronic regions, 
as there are methods of analyzing the downstream effects in terms of amino acid and protein 
alterations. 
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Copy number variation is yet another method of measuring the genome, and involves 
looking at repeated chunks of DNA throughout the genome. Large portions of DNA are 
duplicated multiple times, but the exact number of copies can vary from person to person. Gene 
functionality can be lost if there are fewer DNA copies than normal, and conversely, more copies 
than normal can lead to hyper-activity of a gene. 
2.3 GENOME-WIDE ASSOCIATION STUDIES 
In a genome-wide association study (GWAS), high-throughput genotyping technologies are used 
to assay hundreds of thousands or even millions of SNPs across the genome in a cohort of cases 
and controls.  Since the advent of the GWAS, many common diseases, including late-onset 
Alzheimer’s disease, diabetes mellitus, and heart disease have been studied with the goal of 
identifying the underlying common genetic variations. GWASs are based on the common 
disease-common variant hypothesis which posits that many common variants underlie common 
diseases, each variant increases the risk of disease modestly and an individual manifests disease 
when he or she has a sufficient number of common variants that cumulatively increase the risk of 
disease above a threshold level [6].   
While GWASs have uncovered several thousand SNPs associated with a range of 
common diseases, these SNPs explain only a small proportion of the genetic variability. A 
possible reason for the moderate success of GWASs is the common disease-rare variant 
hypothesis, which posits that many rare variants underlie common diseases and each variant 
causes disease in relatively few individuals with high penetrance [7]. However, larger sample 
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sizes and new analytical method designed specifically for rare variants will likely make GWASs 
useful for detecting rare variants as well [4].  
GWAS data has a number of properties that make it particularly attractive to biomedical 
researchers. First, it is relatively cheap to obtain SNP data. The price of sequencing DNA has 
fallen dramatically over the past 10 years, to the point where a whole genome can be sequenced 
for just a few thousand dollars [8]. Eventually, SNP data will be replaced with full sequence 
data. Second, it is mostly invariant in time and space (ignoring events like tumor mutations). 
Other types of data, such as gene expression, may change over the course of hours or even 
minutes, and can be different depending on the type and location of tissue sampled. A person’s 
DNA sequence is fixed from the moment of conception, and is carried by every cell in their 
body. Finally, the data comes in standardized formats and is available to researches for 
secondary analyses from large repositories such as dbGaP [9]. Moreover, knowledge about 
functional aspects of SNPs continues to grow rapidly, and is readily available to researches from 
knowledge bases such as dbSNP [10]. Hence, genomic variation data is likely to be useful for 
many clinical applications, ranging from diagnostic aids to guiding treatment decisions. 
2.4 ANALYSIS OF GENETIC VARIATION DATA 
The analysis of genomic data occurs often in the service of two goals – (1) biomarker discovery, 
and (2) development of predictive models for assessing risk or predicting the development of 
disease. Given thousands of variables representing the genomic or other biomolecular state of a 
person, we would like to find relatively few variables that can explain the data. Generally, 
biomarkers are sought in the context of a disease or a phenotype, indicating correlation or 
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causation of the disease or phenotype of interest. Biomarkers have a wide array of applications in 
the clinical domain, aiding in risk assessment, disease diagnosis, patient prognosis, and treatment 
decisions The task of GWAS SNP analysis raises some practical concerns that are specific to the 
genomic domain. I discuss some of them here, ranging from genomic population structure to 
computational issues. 
2.4.1 Linkage Disequilibrium 
The phenomenon of linkage disequilibrium (LD) appears in localized regions of DNA, and is a 
measure of statistical correlation between genetic loci. Recombination is the process by which 
genetic material is exchanged between homologous chromosomes, resulting in a new 
combination of alleles. SNPs which are physically near one another are more likely to be 
inherited together, resulting in two loci which carry highly correlated information (strong LD). 
Just as redundant or correlated variables can complicate traditional machine learning tasks, LD 
can confound GWAS analysis. For example, a SNP showing significant association with disease 
may have no causal effect on the phenotype, the culprit instead being a nearby SNP in LD that 
was never measured. It is also possible that multiple SNPs show a strong signal, when in 
actuality all belong to a block of SNPs in strong LD.  One method of dealing with the problem of 
LD is by identifying tag SNPs, each of which represents a block of SNPs in strong LD. By 
analyzing a dataset consisting only of tag SNPs, redundant information is removed. 
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2.4.2 Population Stratification 
Another potential complication in the analysis of GWAS data is population stratification, which 
can cause spurious associations to appear in a dataset. A stratified dataset exhibits systematic 
differences in allele frequencies among the population, caused by factors other than association 
with disease (such as ancestry). Population stratification can be controlled for by filtering out the 
offending allele differences. By performing a cluster analysis (such as PCA), stratified groups 
can be identified, and their particular characteristics can be zeroed out in order to work with an 
unstratified population [11]. 
2.4.3 Computational Complexity 
GWAS datasets are usually high-dimensional and can contain billions of measured genetic loci 
that can consume several gigabytes of memory. As such, the computational complexity of 
analysis methods, both in terms of time and memory required, is a significant issue. Algorithms 
which are of quadratic or combinatorial complexity in terms of the number of features are almost 
always intractable for analyzing a GWAS on a single machine. The linear complexity of most 
univariate methods is one reason why they have found widespread use in the genetics literature. 
One way of addressing the issue of complexity is to utilize multiple processors in a 
parallelized fashion. Some algorithms can be readily programmed so that they can take 
advantage of multiple processors to reduce the runtime. However, other algorithms cannot be 
easily parallelized. Another possibility for certain algorithms is to shift to sample-space analysis 
rather than feature-space analysis. Certain matrix-based algorithms utilize pairwise transitions 
between N samples consisting of d features. With some matrix rearrangement, one can generate 
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an equivalent expression that uses an N2 transition matrix, rather than an intractably large d2 
matrix. For a dataset with N=1,000, and d=500,000, a sample-space representation of the 
transition matrix requires only about 7.6 megabytes of RAM, while a feature-space 
representation would require over 1.8 terabytes! With problems of this size, the limitations of 
even a high-powered computing platform can preclude the use of certain methods. 
2.4.4 Avoiding Bias 
Feature selection in the genomic domain can either be an end in itself or it can be a first step in 
an analysis pipeline, like one that builds a predictive model to be tested on a validation set. It is 
important to consider how selected variants will be used when performing the selection process, 
so as not to introduce unwanted bias. When building a predictive model to describe data, the 
model is usually learned on a training set, and then applied to a held-out test set to evaluate the 
performance. If feature selection is performed as a first step before building the model, it must be 
performed on only the training dataset. Selecting features on the full dataset will produce 
downstream results that are based in part on the testing data, and will often yield an overly 
optimistic estimation of the model’s generalizability. Full-dataset selection is appropriate, 
however, if the selected variants are not being applied directly to the original samples, such as 
the case of mining biological knowledge without building a predictive model. 
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 Figure 1 - Two experimental designs incorporating feature selection and cross-fold validation. 
The highlighted cells in red are the ones being used in each step’s computation, and the boxed sections 
represent processes that are repeated for each of the cross-folds. Bias is introduced in A, because features are 
selected in part on the testing data. Design B avoids bias, and is the preferred design. 
2.5 DIMENSIONALITY REDUCTION 
Because of the high dimensionality of GWAS data, dimensionality reduction methods are of 
importance in the analyses of such data. Though there are many types of dimensionality 
reduction methods, they all have the common goal of reducing the number of variables in a 
dataset. Usually, the goal is to find a parsimonious representation of a high-dimensional dataset 
using fewer features. This can be achieved in one of two ways – by performing feature ranking 
and feature subset selection, keeping relevant variables intact, or by mapping the data to lower-
dimensional space using combinations of variables as the new dimensions (feature construction).  
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Dimensionality reduction is important as a preprocessing step in the analysis of high-
dimensional data, because many classification and prediction algorithms often perform poorly 
with variables that are numerous, noisy, meaningless, or redundant. By first reducing a dataset to 
a smaller number of predictor variables, overfitting can be reduced and statistical performance 
can be improved. Dimensionality reduction also has more specific domain applications, in that 
the features remaining after reduction are good candidates to explore for knowledge about the 
domain. 
2.5.1 Types of Dimensionality Reduction 
Dimensionality reduction, feature ranking, and feature subset selection are related methods that 
seek to remove irrelevant dimensions from a dataset [12]. Dimensionality reduction is the most 
general of the three concepts, and encompasses methods that can remove, combine, scale, or 
otherwise transform variables in order to produce a low-dimensional representation of the 
original data. A dimension in the new representation may not correspond directly to any 
dimension in the original representation, instead being combinations of multiple variables. Such 
dimensionality reduction methods may lead to new variables that are not readily interpretable 
like the variables in the original space, which can be important in the biomedical domain. 
Typically a new variable that is a function of several biomarkers has little meaning in terms of 
biological knowledge; we would instead prefer to identify individual biomarkers of interest. 
Feature selection methods, in contrast, preserve the original dimensions of the dataset. 
This can be achieved by individually ranking the dimensions, or by directly identifying a subset 
of the dimensions. In ranking methods, a score is assigned to each dimension, indicating a level 
of importance. These scores can be directly compared between features, yielding a ranked list of 
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features. This representation is useful for finding features which are individually important. 
While feature ranking methods put features on a scale from most to least important, they do not 
establish a significance threshold. The ranking allows for sequential consideration of potentially 
important biomarkers in a logical order, but does not establish when features become irrelevant. 
Feature subset selection returns a subset of variables that are important in some sense 
from the original set of variables. The subset can be of varying size, but is generally much 
smaller than the original set. Each selected feature corresponds directly to a dimension in the 
original data, making interpretation simple. However, feature selection methods often consider 
the selected subset as a whole, meaning that individual features in the subset may not be 
important on their own. 
Among the methods of dimensionality reduction, feature ranking may be the most 
appropriate in the biomedical domain. In the context of a biomedical dataset, a feature ranking 
method will return a list of biomarkers sorted by their importance. These biomarkers are 
unmodified dimensions which correspond directly to observed variables in the dataset, meaning 
they may be easily interpreted. Furthermore, the top-ranked biomarkers are each important on 
their own, making them good candidates for being causal biomarkers, drug targets, or other 
another kind of individually meaningful variant. 
Feature subset selection methods may also be suitable for GWAS analysis, in that the 
selected features correspond directly to measured biomarkers. However, these biomarkers may 
not be important on their own, making univariate analysis for drug targets or therapy difficult.  
Dimensionality reduction methods which construct new features as some combination of 
the measured variables are generally unsuitable for biomarker discovery in genomic analysis. 
While these algorithms may perform well from a statistical or machine learning standpoint, the 
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lack of feature interpretability is a problem. It must be kept in mind that one of the primary goals 
of GWAS analysis is to find variants of interest, which can then be studied in terms of biological 
function, practical application, and clinical relevance. A variable which is a combination of many 
biomarkers may not give a clear indication of how those biomarkers function individually. A 
constructed variable could also be cumbersome for the task of prediction, because each 
individual biomarker must still be measured in practice.  
2.6 FEATURE SELECTION METHODS 
Feature selection methods perform either feature ranking or feature subset selection. In feature 
ranking a weight or importance value is assigned to each feature and the method returns a list of 
features are ranked according to the weight. In feature subset selection the method attempts to 
identify and return an optimal subset of features. A feature ranking method can be converted into 
a feature subset selection method by choosing a threshold and returning the features with ranks 
lower than the threshold. Typically, it is not possible to convert a feature subset selection method 
into a feature ranking method. 
There are many types of algorithmic methods for feature selection. Supervised methods 
leverage information about the target variable to find variables that are useful for prediction. 
They are usually inductive algorithms which learn a model independent of the unlabeled test data 
Unsupervised methods do not use information about the target, and instead try to find hidden 
cluster structure in the data. These methods try to find a parsimonious representation of the data, 
regardless of target values. In between these two paradigms are semi-supervised algorithms. 
These methods use limited target information and use the structure of the unlabeled data to find 
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relevant variables. In contrast to supervised inductive algorithms, semi-supervised algorithms are 
transductive because models are learned using samples that are not in the labelled training set 
[13].  
A range of selection and feature ranking methods have been developed and a recent 
review of the methods is provided in [14].  There are three major families of feature selection 
methods, namely, filter methods, wrapper methods, and embedded methods. Filter methods 
evaluate features directly, independent of how the features will be used subsequently. For 
example, if features are to be used to develop a classification model, a filter method will select 
features based on some data-dependent criterion and then pass them to an independent classifier. 
Wrapper methods evaluate features in the context of the how they will be used. In terms of 
classification, features are evaluated directly in terms of their ability to improve the performance 
of the classification model. Embedded methods perform feature selection during the classifier 
construction, deriving feature subsets as a direct result of the classification itself. In addition to 
these three main types of methods, there are also combination methods that aggregate several 
feature rankings into a single ranking.  
2.6.1 Filter Methods 
Filter methods assess the relevance of features by considering only the intrinsic properties of the 
data. Univariate filter methods compute the relevance of each feature independently of other 
features. They are computationally fast and scale to high-dimensional data because the 
complexity is linear in the number of features and interactions between features are ignored. 
Typically, such methods compute a statistic or a score for each feature such as chi squared or 
information gain. Multivariate filter methods model correlations and dependencies among the 
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features; they are computationally somewhat slower and may be less scalable to high-
dimensional data. Examples of multivariate methods include ReliefF and Markov blanket feature 
selection. Filter methods are particularly appropriate for GWAS analysis because they are 
agnostic to the final task at hand, and the method used to accomplish it. Filter methods can be 
directly compared by passing their results through the same downstream classifier. 
The chi squared statistic is commonly used in SNP analysis is a univariate filter method 
[15]. This test measures whether outcome distributions are significantly different among SNP 
states, indicating features that have an impact on disease. The chi squared statistic is very fast to 
compute and has a simple statistical interpretation. However, it cannot detect higher-order effects 
such as SNPs that interact to produce an effect on disease. 
Bayesian methods comprise an entire class of GWAS analysis techniques, representing 
data in terms of a well-defined probability distribution. By utilizing prior information and 
observational data, model probabilities may be estimated. In the simplest Naïve Bayes case, all 
variables are assumed independent, and probabilities are assigned according to a maximum a 
posteriori (MAP) estimate. Alternatively, instead of picking a single most likely model, models 
may be averaged according to their likelihood. Other implementations, such as the BD, BDe, 
BDeu, and K2 methods, score Bayesian models according to the data likelihood under a 
particular parameterization, with each method accomplishing smoothing via prior pseudocounts 
slightly differently. Still other score-based methods include minimum description length (MDL), 
minimum message length (MML), Bayesian information criterion (BIC), or Akaike information 
criterion (AIC), each of which seeks to balance model likelihood with the number of parameters 
required to specify it. For these methods, feature selection can be performed by looking for 
models which show a higher likelihood under an assumption of association, rather than 
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independence. Variables which are present in high-likelihood models and absent in low-
likelihood models have the most explanatory power [16]. 
The Relief algorithm [17] is a multivariate filter method that has been applied to SNP 
data to rank SNPs. This method computes the relevance of a SNP by examining patterns in a 
local neighborhood of training samples. The algorithm examines whether, among reasonably 
similar samples, a change in SNP state is accompanied by a change in the disease state. The 
Relief algorithm can detect multivariate interaction effects by means of the neighborhood 
locality measure, but does so at the cost of increased computation time. The Relief algorithm has 
been adapted in several ways for application to SNP data. The most recently described 
adaptations of Relief include Spatially Uniform ReliefF (SURF) [18, 19] and Sigmoid Weighted 
ReliefF (SWRF) [20] that were developed specifically for application to high-dimensional SNP 
data. 
2.6.2 Wrapper Methods 
Wrapper methods contain a feature selection algorithm as well as a way to apply those features 
to a task (e.g., classification). Features are evaluated based on their contribution to the 
performance on the final task, and selection is performed for features which improve 
performance. In this way, the selection process is a “wrapper” around the classification model, 
iteratively searching the feature space for good classification results. As such, the selection and 
classification algorithms are closely tied, and cannot be separated. Comparison of different 
feature selection methods is not completely straightforward with wrapper methods, because the 
classifier is integrated into the selection process [14]. 
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A genetic algorithm (GA) search is one such example of a wrapper method. In this 
method, subsets of SNPs are randomly selected and used for sample classification. The worst-
performing subsets are removed, and the best-performing ones are randomly combined and 
mutated. Because the algorithm directly evaluates SNP subset on their ability to maximize the 
final performance metric (classification accuracy), it is considered a wrapper method. GAs have 
been applied to SNP data to find multilocus effects in GWAS data [21]. 
2.6.3 Embedded Methods 
Embedded methods, like wrapper methods, have an interaction between the feature selection and 
classification processes. While wrapper methods select features and evaluate these subsets in 
terms of classification performance, embedded methods derive features subsets from the 
classification process itself. In a way, the two are even more closely linked. 
A decision tree algorithm is one example of an embedded feature selection technique that 
has been used to find interacting SNPs in GWAS data. Classification and regression tree (CART) 
algorithms build a tree classifiers where decision splits are SNPs and samples are classified at the 
leaf nodes [22]. The CART algorithm greedily chooses the next SNP to split on based on some 
criterion (e.g., Gini impurity). This leads to trees that have highly discriminative SNPs at the top, 
with predictions being refined further down the tree. Because the tree is built in an iterative 
greedy fashion, the feature selection process is intimately tied with the classification 
performance. The   feature search process is embedded in the classification method. 
The random forest (RF) method is an improvement to CART, using multiple decision 
trees to aggregate and smooth performance, reducing the variance in estimates. Many decision 
trees are built on random subsets of the data, and then feature importance overall is computed 
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from the fraction of trees that contain a particular feature. RF has been applied successfully for 
finding biomarkers in biomedical datasets [23, 24]. 
Other embedded feature selection techniques include classification algorithms from 
which a feature scoring can be derived. The support vector machine (SVM), for example, is a 
classification algorithm that builds a maximum-margin decision boundary anchored to relatively 
few training points near the boundary. Several methods leveraging the properties of this 
classification for feature selection have been developed, including a recursive feature elimination 
method (SVM-RFE) [25] as well as gradient-based leave-one-out gene selection (GLGS), which 
is based on the least squares SVM classifier [26]. 
Some feature selection methods have been specifically designed to find epistatic SNPs 
with complex interactions, and a full review is provided in [27]. Some of these methods, such as 
SNP Harvester [28], filter strong main effects before searching for smaller interaction effects. 
Others, like maximum entropy conditional probability modelling (MECPM), utilize a greedy 
search to build higher-order interactions [29]. Still others, like multifactor dimensionality 
reduction (MDR), model epistasis by searching over the space of low-order interactions [30]. 
2.6.4 Combining Feature Rankings 
Each feature selection method has differing strengths and weaknesses, so there can be benefit in 
combining multiple methods. Methods that combine multiple feature selection techniques are 
called ranking aggregation methods. Ranking aggregation methods have been shown to improve 
the rankings obtained from several different feature selection methods [31]. Rankings may be 
aggregated over different algorithms applied to the same data, or even over the same algorithm 
applied to different datasets. 
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Two categories of ranking aggregation methods have been described: i) order-based 
aggregation and ii) score-based aggregation. Ranking aggregation is typically based on order-
based aggregation, that is, only the order of the features in the ranking is taken into account. The 
advantages of order-based aggregation include that order-based aggregation is naturally 
calibrated and scale insensitive. A simple order-based aggregation method is the Borda method, 
which takes two or more ranked lists of attributes, and averages the ranks of each attribute over 
all the lists. Another method is the Condorcet method, which looks at pairwise feature rankings 
on each input list. The top ranked variable is the one which outranks the other variables on a 
majority of the input rankings [32]. 
In score-based aggregation, the scores (weights) of the features from different algorithms 
are combined. Score-based aggregations have to deal with several challenges. One, weights 
produced by each algorithm has to be rescaled to the same range (say, between 0 and 1) so that 
different absolute scales do not influence in the aggregate result. Two, the same weight produced 
by different algorithms might represent different feature relevance and the weights have to be 
calibrated (say, by multiplying the scores of each algorithm by some factor). A score-based 
Borda method exists as well, which averages the scores among all feature lists. In general, rank-
based methods can be converted to score-based methods by normalizing the rank value, while 
the reverse can be achieved by ranking based on scores [33]. 
Table 1 - Feature selection methods that have been applied to GWAS data. 
Method Type Variations Software 
Chi Squared test Univariate  http://pngu.mgh.harvard.edu/~purcell/plink/ 
Logistic Regression Univariate LR + Interaction 
Terms, Sparse LR  
http://www.cns.atr.jp/~oyamashi/SLR_WEB/ 
Support Vector 
Machine (SVM) 
Multivariate Greedy Regularized 
Least Squares 
http://svmlight.joachims.org/ 
http://www.esat.kuleuven.be/sista/lssvmlab/ 
Naïve Bayes (NB) Univariate Model-Averaged 
Naïve Bayes, BIC, 
MDL, K2 
http://www.dbmi.pitt.edu/content/manb 
Decision Tree Univariate   
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Random Forest Multivariate  http://cran.r-project.org/web/packages/randomForest/ 
SNPHarvester Multivariate  http://bioinformatics.ust.hk/SNPHarvester.html 
Maximum entropy 
conditional probability 
modelling (MECPM) 
Multivariate  http://www.cbil.ece.vt.edu/ResearchOngoingSNP.htm 
Multifactor 
Dimensionality 
Reduction (MDR) 
Multivariate  http://www.multifactordimensionalityreduction.org/ 
ReliefF Multivariate Sigmoid-Weighted 
ReliefF, Tuned 
ReliefF 
https://code.google.com/p/ensemble-of-filters/ 
https://github.com/mattstokes42/MoRF 
 
Label Propagation (LP) Multivariate Spectral clustering  
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3.0  ALGORITHMIC METHODS 
This chapter provides background about the label propagation (LP) algorithm and describes in 
detail the version of LP that I implemented for application to genomic data, as well as the 
extensions to LP that I developed. Section 3.1 gives an introduction to LP, with a broad overview 
of the algorithm and its applications. Section 3.2 includes the mathematical and algorithmic 
details of the specific applied version of LP. Other forms of the LP algorithm are described in 
section 3.3, giving a more complete perspective on the general family of propagation algorithms. 
Section 3.4 details the novel algorithmic extensions to LP that I developed, including a single-
score extension, a prior knowledge method, and a ranking combination method. 
3.1 ALGORITHMIC DETAILS 
One approach in machine learning involves representing a dataset as a graph where each node 
denotes a sample and the weight of an edge between a pair of nodes is measure of similarity 
between the two corresponding samples. Many algorithms utilize this representation; however, a 
family of algorithms leverages additional information in the form of labels that are added to 
small set of nodes in the graph. This setting gives rise to a semi-supervised learning wherein the 
additional information is used to label the unlabeled nodes while obeying the constraints 
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imposed by the topology of the graph. This family of methods is called label propagation (LP) 
algorithms. 
LP is a semi-supervised algorithm that can be used for classification and for multivariate 
feature ranking (e.g., ranking SNPs in a case/control genomic data). The data is represented as a 
bipartite graph. A bipartite graph contains two sets of nodes (i.e., sample nodes that represent 
individuals and feature nodes that represent SNP-states in GWAS data) and edges that link nodes 
from one set to nodes in the other set. The sample nodes are labeled with case/control status, and 
the LP algorithm diffuses the labels across graph edges to the feature nodes and back again, until 
a stable solution is reached. The solution results in a final labeling of all nodes in the graph 
which balances the diffusion of the labels with consistency with the original labeling. The 
labeling of the feature nodes can be used to rank the features. 
LP scales well for thousands of samples and features. It has complexity O(kNd), where N 
is the number of samples, d is the number of features and k is the number of iterations required 
for convergence. Typically, k is much smaller than N or d, which makes LP a relatively efficient 
method.  Moreover, LP can handle missing data, as well as both continuous and discrete data. 
Because of its wide applicability, fast running time, and multivariate nature, LP has been 
applied to several bioinformatics problems. For example, LP has been used in breast cancer gene 
expression data in order to find functional modules of co-expressed genes [34]. It has been 
applied to gene function prediction, utilizing known gene functions and interactions to infer the 
function of other genes [35]. It has applied successfully in classifying  patients with Alzheimer’s 
disease using protein array data [36]. To my knowledge, LP has not been applied to SNP data 
outside of my previous work. Unique challenges in the SNP domain include a huge feature space 
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(on the order of hundreds of thousands), as well as the discrete, nominal nature of SNP states (in 
contrast to the continuous nature of expression data). 
3.2 DETAILS OF LP ALGORITHM FOR SNP DATA 
In LP, SNP data are represented as a bipartite graph G = (V, U, E) which consists of two sets of 
nodes V and U where nodes in V represent samples (individuals) and nodes in U represent 
features (SNP-states). Note that if a SNP has three states (major homozygote, heterozygote and 
minor homozygote) then it will be represented by three nodes in U.  In addition to the two sets of 
nodes, the graph contains a set of edges E where each edge links a node in V with a node in U. 
An edge e(v,u)  that links node v with node u is associated with a link weight w(v, u) = 1. These 
edges connect sample nodes to feature nodes, representing the presence of SNP state u in 
individual v. Initial labels y(v) and y(u) are applied to sample and feature nodes, and take values 
{-1, 0, +1}, representing known training information about case/control status (+1 and -1, 
respectively), or a lack of information (0). Labels on sample nodes represent disease status, and 
labels on SNP allele nodes represent a level of association with disease status. An example graph 
initialization is shown in Figure 2. 
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Figure 2 - A small bipartite graph for a hypothetical dataset with five samples and two SNPs. 
The five samples are represented by the nodes at the left (V), and are labeled with case or control status (+1 and -
1, respectively). Each SNP is represented by three nodes at the right (U) with one node for each SNP state. Edges 
represent actual observations in the dataset and connect samples to the SNP states that they exhibit. 
Given the graph initialization, the propagation algorithm finds an optimal assignment of 
node labels f(v) and f(u), which minimizes the objective function 
𝑄𝑄(𝑓𝑓) =  � 𝑤𝑤(𝑣𝑣,𝑢𝑢)� 𝑓𝑓(𝑣𝑣)
�𝑑𝑑(𝑣𝑣) − 𝑓𝑓(𝑢𝑢)�𝑑𝑑(𝑢𝑢)�2 + 𝜇𝜇 ���𝑓𝑓(𝑣𝑣) − 𝑦𝑦(𝑣𝑣)�2𝑣𝑣∈𝑉𝑉 + �(𝑓𝑓(𝑢𝑢) − 𝑦𝑦(𝑢𝑢))2𝑢𝑢∈𝑈𝑈 �(𝑣𝑣,𝑢𝑢)∈𝐸𝐸  
where μ is a parameter controlling the relative effect of the two parts of the cost function. 
The first part of the equation is a smoothness constraint, ensuring that strongly connected 
nodes in V and U get similar labels. Here, d(v) and d(u) are the degree of each node in V and U, 
such that 𝑑𝑑(𝑣𝑣) = ∑ 𝑤𝑤(𝑣𝑣,𝑢𝑢)(𝑣𝑣,𝑢𝑢)∈𝐸𝐸  and 𝑑𝑑(𝑢𝑢) = ∑ 𝑤𝑤(𝑣𝑣,𝑢𝑢)(𝑣𝑣,𝑢𝑢)∈𝐸𝐸 . The second part of the equation 
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is a fitting constraint. For labeled nodes, this ensures that nodes labels are consistent with the 
initial labels. For unlabeled nodes, this term constrains the overall cost. In the discrete-label case 
where f→{-1, 0, +1}, the optimization of this cost function is NP-hard. By relaxing the labels so 
that f→R, however, the optimization of this equation becomes straightforward as derived in Zhou 
[37], and has the solution 𝑓𝑓∗ = (1 − 𝛼𝛼)(𝐼𝐼 − 𝛼𝛼𝛼𝛼)−1𝑌𝑌. Here, I is the identity matrix, Y is the 
vector of initial labels, and S is the normalized connectivity matrix  𝛼𝛼 =
�
0 𝐷𝐷𝑉𝑉−1 2⁄ 𝑊𝑊𝐷𝐷𝑈𝑈−1 2⁄
𝐷𝐷𝑈𝑈
−1 2⁄ 𝑊𝑊𝑇𝑇𝐷𝐷𝑉𝑉
−1 2⁄ 0 �, where W is the |V| x |U| sized matrix of edge weights and DV 
and DU are the |V| x |V| and |U| x |U| diagonal matrices containing node degrees, respectively. 
The parameter α (range [0, 1]) is analogous to the scaling parameter µ (range [0, +∞)) in the 
objective function, with 𝜇𝜇 = 𝛼𝛼
1−𝛼𝛼
. 
While the solution may be computed directly by algebraic evaluation, it requires the 
inversion of a T x T matrix where T is the total number of nodes in the network (T = |V| + |U|). 
This requires between O(T2) and O(T3) time, depending on the inversion method used. Instead, 
an iterative procedure may be used which diffuses node labels from one node set to another. 
First, the normalized graph Laplacian is computed as 𝐵𝐵 =  𝐷𝐷𝑉𝑉−1 2⁄ 𝑊𝑊𝐷𝐷𝑈𝑈−1 2⁄   . This is a special 
encoding of the graph which represents node degrees and adjacency. It has an interpretation as a 
random walk transition matrix, allowing labels to travel across graph edges. The node labels on 
V and U are computed iteratively as 
 𝑓𝑓𝑡𝑡+1(𝑉𝑉) = (1 − 𝛼𝛼)𝑦𝑦(𝑉𝑉) + 𝛼𝛼𝐵𝐵𝑓𝑓𝑡𝑡(𝑈𝑈)   and  𝑓𝑓𝑡𝑡+1(𝑈𝑈) = (1 − 𝛼𝛼)𝑦𝑦(𝑈𝑈) + 𝛼𝛼𝐵𝐵𝑓𝑓𝑡𝑡(𝑉𝑉) 
where α is a user-specified parameter in the range [0, 1] that controls the balance between the 
initial labeling y and the diffusion of current labels f. This procedure ultimately converges to the 
same optimized node labels as the direct algebraic evaluation. The complexity of the direct 
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algebraic evaluation is at least O((|V| + |U|)2), while the complexity of the iterative procedure is 
O(k|V||U|), where k is the number of iterations required for convergence. The exact value of k 
depends on the properties of the graph as well as the convergence criteria, but in practice is 
found to be an order of magnitude less than both |V| and |U| even for large graphs (>100,000 
nodes) and large alpha (>0.9). 
The final labels of the nodes indicate association with the case or control group. Nodes 
with scores near +1 are associated with the case group, nodes with scores near -1 are associated 
with the control group, and nodes with scores near 0 are uninformative. For sample nodes, this 
score can be viewed as a prediction of case/control status based on SNP information. For feature 
nodes, this score can be interpreted as a case/control association measure that can be used to 
identify case/control associated biomarkers. The feature node scores may be ordered to obtain a 
ranking of biomarkers according to their association with case/control status. 
3.3 ADDITIONAL LP ALGORITHMS 
The LP algorithm has a number of implementations and interpretations. The iterative algorithm 
described in Section 3.2 can be expressed succinctly as 𝑓𝑓𝑡𝑡+1 =∝ 𝐿𝐿𝑓𝑓𝑡𝑡 + (1−∝)𝑌𝑌, where L is the 
graph Laplacian, f t contains node labels at iteration t, and Y contains the initial labels. A slightly 
different mathematical formulation can be expressed as  𝑓𝑓𝑡𝑡+1 = 𝐴𝐴−1(𝜇𝜇𝑊𝑊𝑓𝑓𝑡𝑡 + 𝑌𝑌), with the 
weight matrix W representing edge weights (Wii = 0) and the diagonal matrix A containing entries 
𝐴𝐴𝑖𝑖𝑖𝑖 = 𝐼𝐼(𝑖𝑖) + 𝜇𝜇𝐷𝐷𝑖𝑖𝑖𝑖 + 𝜇𝜇𝜇𝜇, where Dii represents node degrees and ϵ is a small constant that prevents 
degenerate, disconnected networks. These two formulations are very similar in their convex 
 31 
quadratic optimization framework, but seek to optimize slightly different cost functions. The first 
optimizes 𝑄𝑄(𝑌𝑌) = ‖𝑓𝑓𝑙𝑙 − 𝑌𝑌𝑙𝑙‖2 + ‖𝑓𝑓𝑢𝑢‖2 + ∝1−∝ �𝐷𝐷−1/2𝑓𝑓�𝑇𝑇𝐿𝐿�𝐷𝐷−1/2𝑓𝑓�, while the second optimizes        
 𝑄𝑄(𝑌𝑌) = ‖𝑓𝑓𝑙𝑙 − 𝑌𝑌𝑙𝑙‖2 + 𝜇𝜇𝜇𝜇‖𝑓𝑓‖2 + 𝜇𝜇𝑓𝑓𝑇𝑇𝐿𝐿𝑓𝑓, with the subscripts l and u indicating portions of the 
vector corresponding to labeled and unlabeled nodes, respectively The main difference between 
the formulations is a somewhat stronger regularization in the former. While both methods seek to 
fit the given training labels on the labeled nodes, the former formulation more strongly drives the 
labels on unlabeled nodes to 0 in the absence of evidence. 
The graph Laplacian L can be viewed as an operator on functions defined over the graph, 
and encodes the network geometry in terms of node connectivity and degree. The eigenvectors of 
L can be used for spectral decomposition of the graph, in that eigenvectors with the smallest 
eigenvalues correspond to the smoothest functions over the graph. It is possible to smooth any 
function on the manifold by projecting it onto p eigenvectors (p < d) with the smallest 
eigenvalues. An algorithm similar to LP is derived by smoothing a graph using eigenvector 
projection, and then fitting labels on the projected graph [38].  
The LP cost criterion in Section 3.2 implicitly utilizes the graph Laplacian in the 
smoothness constraint. For any set of labels y, the smoothness between labels can be measured as 
1
2
∑ �𝑦𝑦𝑖𝑖 − 𝑦𝑦𝑗𝑗�𝑤𝑤𝑖𝑖𝑗𝑗 = 𝒚𝒚𝑇𝑇𝐿𝐿𝒚𝒚𝑖𝑖,𝑗𝑗  [39]. The smoothness constraint penalizes labelings with rapid 
changes in y between strongly connected nodes. It is balanced with the fitting constraint using 
Tikhonov regularization, which minimizes the squared error from the initial labeling [40]. 
Various versions of the label propagation algorithm are obtained by combining different 
smoothness measurements with different error regularizations. An excellent review of the 
different quadratic criteria which can be optimized using iterative label propagation is provided 
in {Bengio, 2006 #319}.   
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Many applications of LP use a  unipartite graph representation, where all nodes represent 
the same type of object (e.g., proteins) and edges represent strength of association between 
objects (e.g., the degree of interaction between a pair of proteins). This is in contrast to the 
bipartite network representation that was described in the Section 3.2, where nodes represent two 
different types of objects (e.g., individuals and SNP alleles) and edges represent which objects 
co-occur (which individuals exhibit which alleles). The unipartite graph has a different geometry 
than the bipartite graph, and is particularly useful for assigning nominal labels to objects, but is 
not directly applicable as a feature selection algorithm. 
One variant of the LP algorithm involves clamping the training labels. In the 
implementation described in Section 3.2, each node’s score is updated in each iteration, 
regardless of whether the node was labeled or unlabeled to begin with. This allows for some 
flexibility in the initial labeling, and is useful in problems where classes cannot be linearly 
separated. In the clamped version of LP, all initially labeled nodes have their scores permanently 
fixed to their initial values. This version of the algorithm is useful in the unipartite 
representations, especially when initial labels are sparse. Clamping the initial values can prevent 
weak diffusion, because the signal sources will not attenuate over time. In the bipartite network 
representation that I use for genomic data, however, the clamped version is unsuitable. All 
sample nodes in the graph begin with labels, and are only one edge away from unlabeled nodes. 
Fixing the labels on all the sample nodes would prevent diffusion through the graph, as any 
information passed back from the feature nodes to the sample nodes would be lost at the clamped 
nodes. Every diffusion path is in effect blocked by a clamped node. 
This clamped version of the algorithm also has a physical interpretation as an electric 
network. The initial node labels can be considered as positive or negative voltage sources, and 
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the edge weights represent electrical conductance between nodes. In this case, the final labeling 
on the unlabeled nodes is equivalent to the voltage that would be observed on those nodes in the 
real-world electric network, obeying physical constraints such as Ohm’s Law and Kirchoff’s 
Law. A similar interpretation can be made with a heat diffusion network, where labels represent 
heat sources or sinks, edges represent thermal conductance, and final labels represent 
temperature. These interpretations provide an intuitive understanding of the algorithm’s behavior 
as it attempts to achieve smooth gradients while being driven toward the initial labels. 
The distance from labeled nodes to unlabeled nodes is an important property of the LP 
graph, which again differs widely from the unipartite to the bipartite representations. In the 
bipartite network, unlabeled nodes are only a single edge away from labeled nodes. In the 
unipartite network, it can take multiple hops to find a labeled node. The average distance to a 
labeled node has a direct impact on the optimal amount of diffusion in the LP algorithm. 
Sparsely labeled graphs with many distant unlabeled nodes will require more diffusion, while 
densely labeled graphs with only nearby unlabeled nodes will require less diffusion. Obviously, 
the bipartite implementation is in the second category, requiring relatively little diffusion to 
spread the training labels to every corner of the network.  
Network geometry has been examined as a means to choose appropriate diffusion 
parameters, with a number of methods proposed. One heuristic method is to build a minimum 
spanning tree over the graph using Kruskal’s algorithm, which iteratively adds the shortest 
possible edge that connects an unconnected component. The neighborhood size is then taken to 
be some fraction (1/3 is suggested) of the shortest edge that connects differently labeled 
components. This allows diffusion to take place mostly within the local class neighborhood [13].  
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The LP method can also be interpreted as a Markov random walk algorithm. If edge 
weights are cast as transition probabilities, it is possible to calculate the probability of arriving at 
any particular node given a starting point and random walk length. Using this information, it is 
straightforward to calculate the probability of arriving at a node with a particular label. The 
random walk length here is crucial to the final solution. As the random walk length increases, the 
steady-state probabilities are approached, but without a long enough walk, we might not find 
labelled examples. It is possible to remove the walk length variable entirely by stipulating that 
the walk continues until a labeled node is found. In this case, the LP algorithm becomes 
equivalent to the Markov random walk, in that the final LP label on an unlabeled node is 
proportional to the random walk probability of arriving at a node with a particular label. Once 
again, in the bipartite network representation, this interpretation is of limited value, because all 
unlabeled nodes are just one step away from labeled nodes.  
The probabilistic interpretation can be extended to the bipartite LP algorithm. The final 
label on sample node represents probability of that individual belonging to the case or control 
class. The label on a feature node represents a random walk probability of reaching a node of a 
particular class. The walk length is directly related to the diffusion parameter α. For α = 0, we 
have a one-step walk that uses no diffusion, and is a simple proportion of cases and controls. For 
α = 1, we have an infinite-step walk, where the starting node is irrelevant (given a connected 
graph).  
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3.4 ALGORITHMIC EXTENSIONS 
Section 3.2 gave the details of the main LP algorithm that I have implemented for GWAS SNP 
analysis. This section provides details of several extensions to the main LP algorithm that I have 
developed, implemented and evaluated. 
3.4.1 LP1 score 
The LP feature scoring method has a few drawbacks relating to the representation of SNP 
features in the bipartite graph. Each three-state SNP is represented by three binary variables, 
resulting in interdependent features. A score is given to each SNP feature (SNP allele), rather 
than to each SNP variable, making the interpretation of the final ranked list more complex. 
Ideally, each SNP should be given a single score to indicate its association with disease. 
The feature scores themselves can be improved. The scores given by the LP algorithm 
exist on an arbitrary (-1, +1) scale which has no meaning outside of the relative ranking for a 
particular experiment. Furthermore, the scores are not associated with a degree of confidence to 
provide a measure of uncertainty about the score.  Preferably, associated SNPs supported by lots 
of evidence should rise to the top of the ranking over associated SNPs with little support. 
In order to overcome these shortcomings, I leveraged the soft labels discovered by the LP 
algorithm. In addition to labeling the unlabeled feature nodes, the method produces a new 
labeling even for the originally labeled sample nodes. I view these soft labels as probabilistic 
class identities, and use them to perform inference. 
Many scoring methods utilize a contingency count table that tabulates observations in a 
dataset. A contingency table for a particular SNP consists of three rows representing the SNP’s 
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three genotypes (AA, Aa, and aa), and two columns representing the phenotypes (case or 
control). The table is filled in simply by tallying every individual’s genotype-phenotype 
combination, resulting in the total count of all observations in the dataset. Scoring methods 
which operate directly on these observed counts include the chi squared statistic, the Naïve 
Bayes model, and the Bayesian Information Criterion. 
Instead of using the counts derived from direct observations, I use partial pseudocounts 
derived from the LP method to fill in the contingency table. By running LP before filling in the 
contingency table, I allow some information to diffuse around the network, softening the hard 
labels. The amount of diffusion is controlled by the parameter α. At α = 0, the algorithm relies 
solely on the initial labeling and allows no diffusion. This setting keeps the hard labeling, and 
produces a count table that is derived only from observations. At α = 1, the propagation process 
dominates, resulting in diffuse, uniform labeling. This leads to an uninformative count table 
where every column has the same distribution of counts. An intermediate setting for α between 0 
and 1 allows for some diffusion, while being sensitive to the initial labeling. 
The soft labeling method results in a contingency table based on partial pseudocounts, to 
which I applied the chi squared test. The result is a likelihood that the phenotype distributions are 
different across the SNP states. This approach provides a single score for each SNP, as well as a 
readily interpretable probability value is a measure of a SNP’s ability to discriminate between 
cases and controls. 
Figure 3 shows the pseudocode for the LP1 algorithm. First, the LP3 scores on each 
sample node (in the range -1 to +1) are converted into case/control pseudocounts (in the range 0 
to 1). These pseudocounts represent the probability of a sample belonging to class 1 (cases) or 
class 0 (controls). These pseudocounts are then used to fill in the contingency table, counting 
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samples only for the features states (SNP alleles) that they exhibit, as dictated by the edge weight 
matrix w. Note that w has three times as many columns as SNPs, representing each SNP as a set 
of three grouped alleles.  Finally, a simple chi squared statistic is computed using the LP3-
derived pseudocount table. 
 
Figure 3 - LP1 pseudocode 
 
Finally, because the method is based on pseudocounts and not just proportions, the 
method is sensitive to the amount of evidence presented. Two SNPs with identical proportions of 
cases and controls would get the same score in the original LP algorithm, but now the actual 
//Turn LP3 sample labels (-1, +1) into case/control pseudocounts (0, 1) 
for i = 0 to #Samples-1 
 Vcount[i, 0] = 1 - (V[i]+1)/2 
 Vcount[i, 1] = (V[i]+1)/2 
//Now use pseudocounts to construct contingency table 
Initialize all arrays (Obs, Row, Col, Exp, LP1) to 0 for all array indices 
//Compute a score for each SNP 
for j = 0 to #SNPs-1 
 //Combine allele-specific LP3 scores 
 for a = 0 to 2 
  //Collect observed pseudocounts (Obs) in 2x3 contingency table 
  for i=1 to #samples  
  //Only collect counts for individuals who exhibit the SNP allele  
  if w[i, 3j+a] > 0 
   Obs[j, 0, a] += Vcount[i, 0]  
   Obs[j, 1, a] += Vcount[i, 1] 
  //Compute table column and row totals (Col and Row)  
  Col[j, a] = Obs[j, 0, a] + Obs[j, 1, a] 
  for d = 0, 1 
   Row[j, d] += Obs[j, d, a] 
 //Compute LP1 statistic over 2x3 contingency table 
 for d = 0, 1 
  for a = 0 to 2 
  //Compute expected table values (Exp) under no association 
   Exp[j, d, a,] = Row[j, d] Col[j, a] / #Samples 
   //Chi squared statistic using observed pseudocounts 
   LP1(j) += (Obs[j, d, a] - Exp[j, d, a,])2/ Exp[j, d, a,] 
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number of cases and controls is important – the SNP with more data has a greater chance of 
having a significant statistic. I call the single-score LP method “LP1”, and refer to the original 
three-score method described in 3.2 as “LP3”. 
 
3.4.2 Incorporation of prior knowledge 
Data-driven methods examine just one dataset, tuning parameters and determining a feature 
ranking based solely on the presented data. These may be complemented by knowledge-driven 
methods, which utilize external sources of knowledge data to inform the learning process. The 
corpus of publicly available knowledge about the genome is large and growing, and contains 
many types of data which can be leveraged in performing feature ranking. I utilized multiple 
sources of prior knowledge in the LP algorithm. 
3.4.2.1 Sources of Knowledge 
There are several kinds of knowledge about the genome. We can glean information about genetic 
polymorphisms based on something as simple as their frequency in the population. It is also 
possible to leverage knowledge about the functions of gene production, to predict downstream 
functional effects of variations in genes. By using the genomes of multiple species, we can infer 
the importance of a specific locus in the genome. 
Minor Allele Frequency 
One simple type of knowledge about a SNP is based on population-wide allele 
frequencies. Using a database independent of the study population (e.g., the Hapmap Project 
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[41]), we can estimate the minor allele frequency (MAF) for each SNP. A SNP’s MAF has been 
shown to be inversely correlated with it being a damaging variant [4]. That is, variants with rare 
minor alleles are more likely to be damaging. Purifying selection against damaging SNP variants 
causes them to appear at lower rates in the population than neutral or beneficial variants. Thus, 
we can have a prior assessment of a SNP’s likelihood of disease association based on its MAF. 
Substitution Effect 
The deleteriousness of exonic SNPs can be predicted based on the structural changes in 
the amino acid sequence, and ultimately the functional changes in the corresponding protein, 
caused by the nucleotide replacement. Nucleotides are parsed in sets of three, called codons, 
each of which codes for one amino acid.  Because there are 64 possible codons (3 positions, 4 
possible nucleotides = 43), but only 20 amino acids (plus a stop codon), there is significant 
redundancy in the amino acid coding scheme. A nucleotide change which does not change the 
corresponding amino acid is called a synonymous substitution, and is unlikely to have an effect 
on the phenotype because the corresponding protein is not altered. Nucleotide substitutions 
which change the amino acid sequence are called non-synonymous mutations, and can have a 
wide range of effects on the phenotype. If the amino acid is changed to one that has relatively 
similar physical properties (such as charge, polarity, hydrophobicity, or volume), there may be 
little effect on the phenotype. On the other hand, a radical change in amino acid properties can 
have a significant effect on the phenotype; for example, an amino acid change can cause 
structural changes in the corresponding protein, rendering it non-functional.  
Possibly the most damaging type of substitution is the nonsense mutation. Here, the 
nucleotide change results in an amino acid codon being changed to a stop codon. This signals the 
biochemical machinery of the cell to stop transcription of the DNA, resulting in a truncated 
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protein. The further the stop codon is from the normal end of the protein, the more genetic 
information goes unused, and the more deleterious the change. Less commonly, a normal stop 
codon may be changed to an amino acid codon, resulting in a run-on protein that typically has 
diminished functionality.  
Several online tools are available for computing the deleteriousness of a SNP allele based 
on the amino acid change caused. Examples include SIFT (Sorting Intolerant From Tolerant 
[42]) and PolyPhen (Polymorphism Phenotyping [43]). 
Conservation 
Another method of predicting a SNP’s importance for biological function stems from the 
analysis of conservation across species. Orthologs are conserved genomic sequences in DNA 
that appear relatively unchanged from species to species. The fact that a sequence has been 
preserved through millions of years of evolution and multiple speciation events suggests that the 
sequence is functionally important and intolerant to change. Therefore, a SNP which occurs in a 
highly conserved region is more likely to be deleterious than a SNP in a non-conserved region. 
Online tools for computing SNP deleterious based on cross-species conservation include PhyloP 
(Phylogenetic p-values [44]) and Genomic Evolutionary Rate Profiling 2 (GERP++ [45]). 
The GERP score is a real-valued number which represents a quantity called rejected 
substitutions (RS). Using the genetic sequences of multiple species, the background neutral 
mutation rate is estimated, along with the actual number of mutations at any given locus. The RS 
value is computed as the number of mutations expected under a neutral mutation rate, minus the 
number of observed mutations. A positive score indicates fewer mutations than expected, i.e., a 
region that is conserved. A score of zero represents a neutrally evolving locus. While a negative 
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score seems to imply faster mutation than expected, it is rather a result of variability in the 
neutral rate estimation, and should be interpreted simply as a lack of evolutionary constraint. 
3.4.2.2 Use of Prior Knowledge in LP 
I employed two types of knowledge in LP, namely, SNP MAFs and GERP scores.  The standard 
LP algorithm described in 3.2 is a spatially uniform method that treats all features identically. I 
developed two methods for incorporating prior knowledge into the LP algorithm. The first is 
through the use of edge weights, and the second is through the use of prior pseudocounts in the 
contingency table analysis. 
The iterative LP diffusion formula propagates labels along all dimensions equally. By 
using prior knowledge, however, it is possible to weight the features according to their prior 
likelihood of being associated with a phenotype of interest. This allows for greater diffusion 
through likely associated nodes, allowing them to have a greater impact on the final scoring. This 
is achieved this through the use of edge weights.  
Previously, each edge w(v,u) in the bipartite graph was given a weight of 1. I instead used 
a relative weighting, where all edges connected to a SNP with a higher prior likelihood of 
association are given higher weights. That is, ∀𝑣𝑣 ∈ 𝑉𝑉,𝑤𝑤(𝑣𝑣,𝑢𝑢) ∝ 𝑝𝑝𝑝𝑝𝑖𝑖𝑝𝑝𝑝𝑝(𝑢𝑢). This allows more 
label propagation through nodes with higher prior likelihood, possibly making them have a 
greater impact on the final labeling. SNP nodes that are unlikely to be associated would permit 
less propagation, having little impact on the overall scoring of other nodes. 
As an alternative to changing the edge weights in the network, prior knowledge is also 
incorporated as prior psuedocount observations. In the chi squared contingency table analysis, 
prior information is added as virtual counts. Simple Laplace smoothing could be performed by 
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adding a count of 1 to each cell, or prior information could be incorporated as a larger number of 
skewed counts. I add these counts to the contingency table at the final LP1 scoring.  
The distribution of these pseudocounts across the 2x3 contingency table should reflect the 
strength of the prior belief. Under an assumption of no prior knowledge (or knowledge against 
association), we would like to reinforce the null distribution of equal disease distributions for 
each SNP state. Ideally, we should also respect the natural distribution of genotypes, which are 
generally in Hardy-Weinberg equilibrium in the absence of association. So, in order to reinforce 
the notion of no association, I distribute the prior counts (P) as follows, where d represents the 
prevalence of disease in the dataset and q represents the MAF of the SNP. 
 
Table 2 - Null distribution of prior counts. 
 AA Aa aa 
D- (1-q)2)(1-d)P 2q(1-q)(1-d)P q2(1-d)P 
D+ (1-q)2dP 2q(1-q)dP q2dP 
 
For SNPs that do have prior evidence, the pseudocounts should skew accordingly. The 
column totals are fixed according to HWE, but row totals are not. For both the MAF and GERP 
score, we operate under the assumption that the minor allele is the one increasing risk of disease. 
So, as prior belief in association increases, counts move from D+ to D- in the AA column, and 
from D- to D+ in the aa column. 
For the GERP score, we assume that scores less than 0 indicate neutrally evolving sites 
that should have the null distribution of no association reinforced. We then normalize positive 
scores from the range [0, 6.4] (where 6.4 is the maximum GERP score in practice) to the range 
[0, 1], and use this as a factor m for moving pseudocounts away from the null distribution. The 
MAF scoring follows a similar method, normalizing MAFs from the range [0, 0.5] to the range 
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[0, 1] and setting the factor m as 1 minus the normalized MAF. For both GERP and MAF scores, 
an m factor near 0 indicates a prior belief of no association, while a factor of 1 indicates 
maximum possible prior belief in association. Using the m factor, I modify the null count table 
(Table 2) with prior pseudocounts a through f as follows. 
Table 3 - Null prior count table (left, see Table 2) and prior count table with a prior belief of strength m 
(right). 
 AA Aa aa  
→ 
 AA Aa aa 
D- a b c D- a +m2d b c(1-m2) 
D+ d e f D+ d(1-m2) e f +cm2 
For an m factor of 0 (no association), we just add the null count table to the actual 
distribution. As m increases toward 1, counts move up in the first column and down in the last 
column, indicating disease association with the minor allele. When m = 1 (the highest possible 
association factor), the AA column has 0 pseudocounts added to the D+ row and the rest added to 
the D- row, while the opposite is true for the aa column. The exponent on the m term in the 
contingency table significantly upweights SNPs with high priors (near m = 1), while having less 
effect on SNPs with low and moderate priors. 
3.4.3 Combining feature rankings 
Each feature selection algorithm has its own strengths and weaknesses. In previous work, I found 
that the univariate method chi squared tends to identify strong single-variable signals while 
missing more subtle multivariate effects. Multivariate ranking methods including LP, on the 
other hand, tend to rank the strong univariate signals somewhat lower, instead favoring variables 
with smaller independent effects. This suggests that combining the rankings from univariate and 
multivariate methods may produce a ranking that is superior to either the univariate or the 
multivariate method alone. 
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To this end, I combined feature scores from multiple algorithms. With the algorithmic 
extension, the LP scores are given SNP by SNP on a probabilistic scale, as opposed to three 
scores per SNP on an arbitrary scale. These scores can be used for both order-based and score-
based rank aggregation. I combined scores from chi squared (univariate method) and from LP 
(multivariate method), as well as from SLR and LP using the Borda methods of combining ranks 
and scores. 
Given two variable scorings, the Borda method generates a third variable scoring that is a 
combination of both. For the score-based, Borda method, the variable scores are simply averaged 
together arithmetically. This is simple for variable scoring methods that operate on the same 
scale, e.g., a probabilistic [0, 1] range. The rank-based Borda method is very similar, except that 
instead of directly averaging variable scores, the cardinal variable ranks are determined from the 
scores, and it is the ranks that are averaged. The rank-based version has the advantage of being 
insensitive to the absolute scale of the scoring methods used. 
Because LP1 and the chi squared test use the same scale for their scoring metric (chi 
squared is in fact equivalent to LP for α = 0), the feature scores may be combined directly. The 
SLR method’s scores, in contrast, are just feature coefficients in the regression model, and don’t 
map to a probabilistic scale. Because of this, we do not perform score-based Borda combination 
for LP1 and SLR. Instead, we use only the rank-based Borda method to combine LP1 and SLR. 
Because the SLR method is implicitly selective, most of the variables get identical scores of 0. 
When converting to a rank, all of these non-selected variants are assigned the maximum rank, 
which is just the number of variables in the dataset. 
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4.0  EXPERIMENTAL METHODS 
This chapter describes the experimental methods used to evaluate the feature selection 
algorithms. Section 4.1 describes the eleven datasets used for analysis, Section 4.2 describes the 
performance metrics used to quantify each algorithm’s performance, and Section 4.3 details the 
comparison algorithms used. 
4.1 DATASETS 
For the experiments, I used a synthetic SNP dataset, a semi-synthetic SNP dataset and nine 
GWAS SNP datasets.  The synthetic dataset is low-dimensional, the GWAS datasets are high-
dimensional with hundreds of thousands of SNPs, and the semi-synthetic dataset has a moderate 
number of features. All datasets have one binary target variable that denotes the case/control 
status of an individual, and many trinary SNP variables that indicate SNP alleles. The datasets 
are summarized in Table 4, and more details about the datasets are provided in the following 
subsections. 
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Table 4 - Summary of datasets. 
Dataset Cases Controls SNPs 
Synthetic 134 866 1,000 
Semi-synthetic 
(GAW17) 1,100 5,870 24,487 
Alzheimer’s Disease 
(TGen) 861 550 234,665 
Alzheimer’s Disease 
(ADRC) 1,291 958 682,685 
Bipolar Disorder 
(WTCCC) 1,868 2,938 394,290 
Crohn’s Disease 
(WTCCC) 1,748 2,938 393,861 
Coronary Artery 
Disease (WTCCC) 1,926 2,938 394,265 
Hypertension 
(WTCCC) 1,952 2,938 393,549 
Rheumatoid Arthritis 
(WTCCC) 1,960 2,938 393,502 
Type 1 Diabetes 
(WTCCC) 1,963 2,938 394,217 
Type 2 Diabetes 
(WTCCC) 1,924 2,938 394,283 
 
4.1.1 Synthetic dataset 
The synthetic dataset contains 1,000 SNVs and a binary phenotype that is a function of 35 
“causal” SNVs. Of the 35 causal SNVs, 10 of them were modeled as common SNPs with MAFs 
that were sampled uniformly from the range 0.0500 to 0.5000 with odds ratios in the range 1.05 
to 1.50. The other 25 SNVs were modeled as rare SNVs that were sampled uniformly from the 
range 0.0001 to 0.0100 and odds ratios in the range 2 to 10. The remaining 965 SNVs (“noise” 
SNVs) ranged from common to rare, but do not have an effect on the phenotype. Phenotype 
status was assigned using an additive threshold model, with each causal SNV conferring an 
independent risk of disease. We created a set of 1,000 individuals and in that set 13.3% of 
 47 
individuals had a positive phenotype. The comparable number of samples and features make this 
model fairly robust to variations across instantiations of the data, reducing the need for multiple 
runs to observe “average” statistical performance. 
4.1.2 GAW17 semi-synthetic dataset 
The GAW17 dataset is a mini-exome semi-synthetic dataset that was constructed for the Genetic 
Analysis Workshop 17 that was held in 2010 at Boston, Massachusetts. The genomic data was 
obtained from 697 unrelated individuals whose exomes were sequenced in the 1000 Genomes 
Project and the genomic data consists of 24,487 autosomal SNVs that map to 3,205 genes [46, 
47]. This is a mini-exome dataset since the 3,205 genes comprise a subset of all human genes.   
The synthetic portion of the dataset consists of four quantitative risk factors that were 
simulated as normally distributed phenotypes. The genes associated with each of the risk factors 
were chosen from the cardiovascular disease (CVD) risk and inflammation pathways. Finally, a 
binary disease phenotype representing CVD was modeled as a function of the four quantitative 
risk factors. In the synthetic phenotype data, the values of three of the four risk factors (named 
Q1, Q2, and Q4) and the binary phenotype were provided for each individual. The values of the 
risk factor Q3 were not provided to simulate a latent factor. Q1 was modeled as a function of age 
and 39 SNVs in nine genes and included a genotype-smoking interaction. Q2 was modeled as a 
function of 72 SNVs in 13 genes and was not influenced by age, sex, or smoking status. Q4 was 
modeled as a function of age, sex and smoking; while it had a genetic component; it was not 
influenced by any of the SNVs in this dataset. The latent factor Q3 was influenced by 51 SNPs in 
15 genes. A total of 200 replicate datasets of are provided.  In each replicate an individual had 
the same genotypes and the phenotype was simulated. 
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This dataset simulated a common disease as function of both rare and common SNVs 
based on the current thinking that both common and rare SNVs contribute to the genetic basis of 
common diseases. Over 75% of the SNVs in the GAW17 have MAF below 1%, and nearly 40% 
have MAF below 0.1% (see Figure 4). 
 
Figure 4 - Distribution of MAFs in the GAW17 data shows many rare variants. 
For my experiments, I pooled the data in the first ten GAW17 replicates to create a 
dataset with 24,487 SNVs and 6,970 individuals. I used the binary Q2 risk factor as the 
phenotype of interest, because its underlying model uses only genetic variables and does not 
include any latent features. 
4.1.3 Late-onset Alzheimer’s disease datasets 
Two late-onset Alzheimer’s disease (LOAD) GWAS datasets were used in the experiments.  
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TGen Dataset 
The TGen GWAS data comes from the Translational Genomics Research Institute 
(TGen) located in Phoenix, Arizona. This dataset was originally collected and analyzed by 
Reiman et al. [48]. The genotype data were collected on 1,411 individuals, of which 861 had 
LOAD and 550 did not. Of the 1,411 individuals, 644 were APOE 34 carriers (one or more 
copies of the e4 allele) and 767 were non-carriers. Of the 1,411 individuals, 1,047 are brain 
donors in whom the status of LOAD or control was neuropathologically determined, and 364 are 
living individuals in whom the status was clinically determined. The average age of the brain 
donors at death was 73.5 years for LOAD and 75.8 years for controls. The average age of the 
living individuals is 78.9 years for LOAD and 81.7 years for controls. The target phenotype 
variable is the presence or absence of LOAD. In this dataset, 61% (861 of 1,411) had LOAD. In 
the original study an Affymetrix chip was used with 502,627 SNPs for each individual. After 
quality control 234,665 autosomal SNPs were retained for analysis.  
ADRC Dataset 
The ADRC LOAD dataset comes from the University of Pittsburgh Alzheimer’s Disease 
Research Center (ADRC) [15]. This dataset consists of 2,229 individuals of which 1,291 were 
diagnosed with LOAD and 938 were healthy age-matched controls. All of the patients met 
National Institute of Neurological and Communication Disorders and Stroke (NINCDS) and 
Alzheimer’s Disease and Related Disorders Association (ADRDA) criteria for probable or 
definite AD. In the original study 1,016,423 SNPS were measured and after quality controls were 
applied by the original investigators 682,685 SNPs located on autosomal chromosomes were 
retained for analysis. 
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4.1.4 WTCCC GWAS datasets 
The Wellcome Trust Case-Control Consortium (WTCCC) is a British study covering thousands 
of individuals and spanning multiple diseases. I used the WTCCC phase 1 datasets, which 
consists of bipolar disorder (BD), coronary artery disease (CAD), Crohn’s disease (CD), 
hypertension (HT), rheumatoid arthritis (RA), type 1 diabetes (T1D), and type 2 diabetes (T2D). 
Each disease dataset contains genotypes for approximately 2,000 cases. In addition two sets of 
healthy controls are provided that contain SNPs for approximately 3,000 individuals. After 
quality control filters were applied, individuals in each dataset contain approximately 400,000 
SNPs.  
4.1.5 Quality control for GWAS datasets 
Each GWAS dataset was preprocessed by applying a number of quality control criteria. Both 
individuals and SNPs were filtered for missingness (<1% for SNPs, <5% for individuals) to 
eliminate poor-quality data points, and the remaining missing genotype values were imputed. 
SNPs were further filtered according to minor allele frequency (MAF > 0.01). Some SNPs 
passed full data-set MAF filters, but appeared monogenic in cases or controls, so the MAF filter 
was applied to cases and control separately. SNPs were further filtered according to Hardy-
Weinberg equilibrium p-value. Finally, datasets were examined for population stratification. The 
PLINK software [49] was used to perform the principal component analysis (PCA) for each 
dataset, and clustering was performed using the first two principal components. Though mixed 
groups appear in the PCA plots, there is no significant clustering of cases and control separately, 
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indicating that these datasets are suitable for analysis without requiring adjustment for population 
stratification (see Figure 5). 
 
Figure 5 - Principal Component plots for select datasets. 
While the datasets show some population structure, individuals are not stratified by case/control status 
4.1.6 Prior knowledge sources 
SNP minor allele frequencies and GERP scores were obtained using the Genome Variation 
Server (GVS). This online portal can be used to submit batch queries to the dbSNP server, 
downloading the relevant information for roughly half a million variants in about 24 hours. 
Records for nearly all SNPs in each dataset (>99.5%) were retrieved successfully, with both a 
GERP score and a MAF for each mapped rsID. SNPs that did not have an associated MAF or 
GERP score in the database were set to the mean score value for that dataset. As expected, 
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GERP scores were centered near a null score of 0, indicating a neutral mutation rate. MAFs were 
generally distributed uniformly between 5% and 50%, but showed a deficit of rare SNPs with 
MAF < 5%. No correlation was found between the MAF and the GERP score in any dataset. 
  
Figure 6 - Plot of GERP score versus MAF for each SNP in the TGen dataset, with distribution histograms. 
There is no correlation between the measures, as indicated by the trend line in red. All other datasets 
showed similar distributions of scores, with no correlation between MAF and GERP 
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4.2 EVALUATION 
Several methods are available for evaluating the performance of algorithms that are used for 
biomarker ranking and biomarker discovery. The evaluation methods that I used included 
precision-recall curves, evaluation of predictive performance using Receiver Operating 
Characteristic (ROC) curves, reproducibility of biomarkers across datasets, evidence of 
biological validity obtained from the literature for top-ranked biomarkers, and computational 
efficiency. 
4.2.1 Precision-recall curves 
Biomarker selection can be viewed as information retrieval with binary classification. In this 
context, precision (also called positive predictive value) is the fraction of selected biomarkers 
that are true (or causal) biomarkers, and recall (also called sensitivity) is the fraction of true 
biomarkers that are retrieved. High precision indicates that an algorithm selected substantially 
more true biomarkers than irrelevant biomarkers, while high recall indicates that an algorithm 
selected most of the true biomarkers.  
In the context of ranked biomarkers, appropriate sets of selected biomarkers are naturally 
given by the top k ranked biomarkers. For each set of k biomarkers, precision and recall values 
can be plotted on the y-axis and x-axis respectively to give a precision-recall (PR) curve. In 
addition to the PR curve, it is also possible to view the ranking in terms of an ROC curve which 
utilizes the true positive rate (sensitivity) and false positive rate (fraction of negatives which are 
incorrect). By modifying the feature selection threshold value, it is possible to compute the TPR 
and FPR over all possible settings, yielding the ROC curve. 
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Since computation of precision and recall requires knowledge of true biomarkers in a 
dataset, this evaluation is performed only for experiments that use synthetic and semi-synthetic 
datasets where the true SNPs are known. 
4.2.2 Evaluation of predictive performance 
Meaningful features should be predictive of disease, and classifiers developed from highly 
predictive SNPs should have good performance in discriminating between cases and controls. I 
evaluated the predictive performance of the top-ranked SNPs for each feature ranking method 
and dataset by measuring the performance of a series of classification models that were 
developed using progressively larger number of top-ranked SNPs.  Given a set of top-ranked 
SNPs obtained from a ranking method applied to a training dataset, I applied a kNN 
classification algorithm to a test dataset containing genotypes for the corresponding SNPs. I 
evaluated the performance of the classification algorithm using fivefold cross-validation. The 
dataset was randomly partitioned into five approximately equal sets such that each set had a 
similar proportion of individuals who developed the disease. I applied the ranking algorithm on 
four sets taken together as the training data, and evaluated the top-ranked SNPs’ predictions on 
the remaining test data.  I repeated this process for each possible test set to obtain a prediction for 
each individual in the dataset. I used the predictions to compute the area under the Receiver 
Operating Characteristic curve (AUC) which is a widely used measure of classification 
performance. The LP algorithm was evaluated using α=0.25, which was found to have the best 
classification performance among values tested between 0.0 and 0.9. This setting puts more 
emphasis on matching the case/control training labels while still utilizing some network 
diffusion, and is suitable for finding discriminative SNPs. 
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The kNN algorithm is a simple non-parametric classification algorithm that utilizes 
pairwise distances between a query sample and the training samples. For SNP data, the pairwise 
distance simply counts the number of SNPs which have different values between the query and 
reference individuals. The classification result for the query sample is then computed as the 
average target value among the k most similar training samples to the query. I utilized a setting 
of k = 10. The kNN algorithm is suitable for a small number of features, but suffers from the 
curse of dimensionality as irrelevant, noisy or redundant variables are added to the dataset. 
Because of this, I perform feature selection as a first step, using the downstream kNN 
classification performance as a proxy for evaluating the feature selection itself. 
4.2.3 Reproducibility of biomarkers 
I evaluated the feature ranking methods for reproducibility across the two LOAD datasets. The 
two datasets were reduced so that they contained only the genotypes for the 64,984 SNPs that 
were common to both. After running the feature ranking methods separately on each of the 
reduced datasets, the ranked SNPs were evaluated for reproducibility as follows. Given two 
ranked list of SNPs obtained by applying a feature ranking method to the two reduced datasets 
the ranked lists were examined for common SNPs in the top-ranked 10 SNPs, 50 SNPs, 100 
SNPs, and so on. Reproducibility was calculated as the number of SNPs in common to both lists 
divided by the total number of SNPs in a list, yielding a value in the range from 0 (no SNPs in 
common) to 1 (both lists contain exactly the same SNPs). This measure only checks for presence 
or absence of SNP in a list, and ignores actual ranks within the list. Since only LOAD had two 
separate datasets, reproducibility was evaluated only across these two datasets.  
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4.2.4 Evidence of biological validity 
For the GWAS datasets, I examined the top-ranked SNPs for biological significance and 
evidence of previously documented association with disease. I used several publically available 
databases and resources including SNPedia [50], GeneCards [51], and dbSNP [10] to identify 
evidence linking variants and diseases. In addition to SNPs directly named in the literature as 
having an association with disease, I also considered a wider range of plausible associations. For 
each SNP, I searched whether it was in strong linkage disequilibrium with disease-related SNPs, 
whether the SNP was in a disease-related gene, whether the associated gene was part of a 
strongly conserved, disease-related family, or whether the variant has been associated with a 
similar condition or a plausible pathway. 
 The actual protocol for identifying literature evidence required several steps. First, the 
each SNP’s rsID was entered into Google, and the top 20 hits were examined for mention of the 
disease of interest or similar diseases/symptoms (e.g., neurological conditions for Alzheimer’s 
disease datasets, bowel-related conditions for Crohn’s disease dataset). If this search failed to 
produce evidence, another search was run using both the rsID and disease name as search terms 
(e.g., “rs1234 bipolar disorder”), and the top 20 hits were examined. The rsID was entered into 
dbSNP to identify the chromosome, and if applicable, the associated gene of the locus. The rsID 
was also researched using SNPedia, which returns citations of literature mentioning the SNP. If 
no literature association was found at the SNP level, I searched for association at the gene level 
(for exonic SNPs). Similar Google searches were run as above, replacing the rsID with the gene 
name, and searching for literature citations and gene information on the GeneCards database.    
 Due to the time required for manual validation of SNPs, I evaluated all algorithms’ top-
ranked SNPs for the TGen and ADRC LOAD datasets, but only the LP1 extension’s results on 
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the rest of the GWAS datasets. The chi squared test was also evaluated on the CD and HT 
WTCCC datasets for baseline comparison. These datasets were chosen because the performance 
of the LP1 algorithm was at its highest on the CD dataset, and showed somewhat poorer 
performance on the HT dataset.  
4.3 COMPARISON ALGORITHMS 
Three algorithms were used as comparison methods for LP. The SWRF algorithm was only 
applied the two LOAD datasets; while the chi squared test and SLR were applied to all datasets. 
4.3.1 Chi squared test 
The chi squared test is a commonly used univariate statistic that has a probabilistic interpretation. 
The test tabulates observations in a contingency table, which records co-occurrences of variable 
states and the target variable. The chi squared statistic computes the deviance from the null 
contingency table, in which all variable states have the same distribution of the target variable. 
This is done by determining the “expected” value for each cell in the contingency table, which is 
the row total multiplied by the column total, divided by the total number of samples. The chi 
squared statistic is then computed as 𝜒𝜒2 = ∑ ∑ (𝑂𝑂𝑖𝑖,𝑗𝑗−𝐸𝐸𝑖𝑖,𝑗𝑗)2
𝐸𝐸𝑖𝑖,𝑗𝑗𝑐𝑐𝑗𝑗=1𝑟𝑟𝑖𝑖=1 , where r is the number of rows in 
the contingency table and c is the number of columns, Oi,j is the observed value in the ith row 
and jth column, and Ei,j  is the expected value in the same cell. The resulting statistic can be 
compared to the chi squared distribution to determine the probability of association between the 
SNP’s alleles and the target variable. 
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4.3.2 Sigmoid Weighted ReliefF 
The Relief algorithm was first described by Kira and Rendell [17] as a simple, fast, and effective 
approach to attribute weighting. The output of the Relief algorithm is a weight between -1 and 1 
for each attribute, with more positive weights indicating more predictive attributes. The weight 
of an attribute is updated iteratively as follows. A sample is selected from the data, and the 
nearest neighboring sample that belongs to the same class (nearest hit) and the nearest 
neighboring sample that belongs to the opposite class (nearest miss) are identified. A change in 
attribute value accompanied by a change in class leads to upweighting of the attribute based on 
the intuition that the attribute change could be responsible for the class change. On the other 
hand, a change in attribute value accompanied by no change in class leads to downweighting of 
the attribute based on the observation that the attribute change had no effect on the class. This 
procedure of updating the weight of the attribute is performed for each sample in the dataset. The 
weight updates are then averaged so that the final weight is in the range [-1, 1]. The attribute 
weight estimated by Relief has a probabilistic interpretation. It is proportional to the difference 
between two conditional probabilities, namely, the probability of the attribute’s value being 
different conditioned on the given nearest miss and nearest hit respectively.  
In contrast to most other feature ranking or feature selection methods that consider 
attributes univariately, Relief algorithms are able to capture attribute interactions because the 
global distance measure which defines sample proximity is a multivariate function. However, 
because the nearest neighbors are identified by a distance measure that incorporates all attributes, 
the presence of many irrelevant or noisy attributes (as in SNP data) can lead to suboptimal 
identification of nearest neighbors. 
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I used a variant of ReliefF that I developed called sigmoid weighted ReliefF (SWRF). It 
utilizes a soft neighborhood inclusion threshold, and has been shown in synthetic data to have 
greater power than ReliefF [20] for selecting predictive variables. 
4.3.3  Sparse Logistic Regression 
The logistic regression (LR) algorithm is an algebraic method that learns a function to map the 
input variables (X) to the target variable (Y). Coefficient-weighted variables (wX) are summed 
and passed through a logistic function to perform a mapping from inputs to an estimated target 
classification (𝒀𝒀�). The ideal variable coefficients minimize the residuals obtained when mapping 
inputs to target (�𝒀𝒀� − 𝒀𝒀�𝑝𝑝), where p is a regularization factor. In contrast to the linear regression 
model, the optimal solution to the logistic regression model cannot be expressed in closed form, 
so an iterative optimization technique such as Newton’s method must be used. The logistic 
regression model space is much larger than the linear regression model space, and can represent 
many more function. 
The cost criterion that the LR method optimizes can be altered to change its performance. 
By increasing the regularization of the cost equation, the LR algorithm will give lower 
coefficients to most variables. So-called sparse solutions are regularized such that the weights of 
many variables are pulled to 0, eliminating them from the model entirely. One sparse logistic 
regression (SLR) method utilizes automatic relevance detection to inform the iterative 
optimization procedure. The SLR algorithm’s current estimate of variable weights is used to alter 
the prior distribution over which weights are estimated for the next iteration. Variables with low 
weights have their prior distribution shrink around 0, eventually eliminating many of the 
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variables entirely. I used a MATLAB implementation of SLR which was developed for 
analyzing high-dimensional fMRI voxel data [52]. 
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5.0  EXPERIMENTAL RESULTS 
This section provides experimental results of applying the algorithms described in Chapter 3.0 
using the evaluation metrics and datasets described in Chapter 4.0 Section 5.1 gives results of the 
original LP3 algorithm and the LP1 extension on the synthetic, semi-synthetic, and GWAS 
datasets. Section 5.2 provides results from the use of prior knowledge in the LP1 algorithm, and 
Section 5.3 provides results from the feature ranking combination method. 
5.1 EVALUATION OF LP3 AND LP1 
This section describes the evaluation of two LP algorithms that I developed for application to 
genomic data. The LP3 algorithm represents the data as a bipartite graph in which each SNP is 
represented by three nodes, with each SNP state being score differently. The LP1 algorithm also 
represents the data as a bipartite graph; however each SNP receives a single score representing 
association over all SNP states. My goal in developing LP1 was to adapt the LP algorithm to 
output directly a single rank for each SNP. The two algorithms are described in detail in Chapter 
3.0  
The performance of LP1 and LP3 algorithms were compared with three control 
algorithms – chi squared, SWRF and SLR. Each algorithm were evaluated on synthetic data, 
semi-synthetic GWA17 data, two LOAD GWAS datasets and WTCCC GWAS datasets on seven 
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diseases.  From the GWAS datasets, results for the SWRF algorithm are presented only for the 
LOAD datasets because SWRF had very long runtimes. Given that the WTCCC datasets have 
about double the number of SNPs and more than double the number of samples compared to the 
LOAD datasets, the O(N2d) SWRF algorithm was estimated to take 10 times as long to run, 
resulting in intolerable month-long computation times for a single fold on a single dataset. I 
replaced the SWRF algorithm with the SLR algorithm as a multivariate control algorithm since it 
has been recently shown in the literature to have good performance on GWAS data and has 
shorter running time than SWRF [52]. 
5.1.1 Synthetic Data 
On the synthetic data, the algorithms were evaluated in their ability to identify the 35 causal 
SNVs (that include 10 common SNVs and 25 rare SNVs) using precision-recall and ROC 
curves, but not in terms of predictive performance. The LP algorithms were run with multiple 
settings for the α parameter.  
 
Figure 7 - Precision-recall curves and ROC plots for recovering 35 causal SNVs in synthetic data. 
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The SLR method performed the best on this dataset, with very good precision and recall. 
LP3 and SWRF have the next best performances, followed by LP1 and chi squared (see Figure 
7). As the LP1 method’s α parameter increases beyond 0.5, its performance rapidly decreases. 
Performances in the range of α = [0, 0.5] were roughly equivalent, with α = 0.25 performing 
marginally better than other parameterizations. All of the algorithms easily recover the 10 
common SNVs with smaller effect sizes, as evidenced by the dropoff point on the precision-
recall plot after all common variants have been found, at 10/35  (~0.285) on the x-axis. None of 
the algorithms ranked the rare SNVs highly, and have rapidly decreasing precision after 
identifying approximately 70% of the causal SNVs. 
5.1.2 GAW17 Data 
On the semi-synthetic GAW17 data, the algorithms were evaluated in their ability to identify the 
72 causal SNVs in terms of precision-recall curves and predictive performance. Overall, all 
algorithms had poor precision-recall performance, as shown in Figure 8. The LP1 algorithm 
performed somewhat better than the other methods, but still had low precision. The LP3 
algorithm did no better than random. Many SNP genotypes were not observed in the data, due to 
the rarity of the alleles. These disconnected nodes in the graph retain their initial scores of 0, and 
are all indistinguishable in rank. 
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 Figure 8 - Precision-recall and ROC results for GAW17 data. 
The poor PR performance is due to the observation that the majority of the causal SNVs 
are very rare in this dataset, and some of them are private mutations in that the minor 
homozygote occurs only in one individual.  In addition, the phenotypic model used in this dataset 
is multivariate and complex. 
Without the ability to recover the causal variants, the predictive performance is also very 
poor, as is expected. None of the algorithms do better than random classification until at least 50 
SNVs are used, and even then it is only a marginal improvement. The LP1 algorithm performs 
slightly better than chi squared and SLR for 100, 500, and 1000 features, but the difference is not 
significant. Classification AUCs plateau around 0.6 as the number of SNVs added to the 
classifier is increased. Table 5 Table 5shows the kNN prediction AUCs for the GAW17 data. 
Table 5 - Prediction AUCs on GAW17 data. 
Method 
Features Used 
1 2 5 10 50 100 500 1000 
ChiSq 
0.4995 
±0.0595 
0.5006 
±0.0599 
0.5416 
±0.0601 
0.5415 
±0.0607 
0.5628 
±0.0603 
0.5703 
±0.0591 
0.5867 
±0.0650 
0.5717  
±0.0656 
SLR 0.5030 ±0.0597 
0.5311 
±0.0601 
0.5401 
±0.0601 
0.5412 
±0.0607 
0.5598 
±0.0607 
0.5775 
±0.0591 - - 
LP3  
(α = 0.25) 
0.4934 
±0.0604 
0.5128 
±0.0605 
0.5015 
±0.0602 
0.5184 
±0.0605 
0.5244 
±0.0620 
0.6051 
±0.0622 
0.6001 
±0.0622 
0.5524 
±0.0607 
LP1 
(α = 0.25) 
0.5134 
±0.0605 
0.5311 
±0.625 
0.5311 
±0.0625 
0.5311 
±0.0627 
0.5650 
±0.0607 
0.5806 
±0.0627 
0.5963 
±0.0631 
0.6058 
±0.0654 
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5.1.3 GWAS Datasets 
The algorithms were evaluated on a total of nine GWAS datasets in terms of predictive 
performance, in terms of biological significance of the top-ranked SNPs (evidence of 
documented association with disease), and in terms of computational efficiency. In addition, LP1 
was evaluated on the two LOAD datasets for feature reproducibility.  
5.1.3.1 Predictive Performance 
Each feature ranking algorithm was applied to each GWAS dataset, and the top-ranked SNPs 
were used to construct a k-nearest neighbor classifier. This was done using fivefold cross-
validation, repeating the process of selecting features on four training folds and classifying the 
samples in the remaining test fold. Experiments were conducted where classifiers were 
constructed with increasing number of top-ranked SNPs; the number of SNPs ranged from 1 top-
ranked SNP to 1000 top-ranked SNPs. The AUCs from all experiments, along with confidence 
intervals, are given in Appendix A. A portion of these results are presented in Table 6, which 
shows the AUC results for classifiers that were constructed using a small to moderate number of 
top-ranked SNPs (5, 10, 50 and 100 SNPs). 
Table 6 - Prediction AUCs for nine GWAS datasets. 
Features Algorithm 
Dataset 
TGen ADRC BD CAD CD HT RA T1D T2D 
5 
ChiSq 0.7220 0.7433 0.6056 0.7702 0.6225 0.5519 0.7013 0.7448 0.7780 
SLR 0.7291 0.7100 0.5975 0.6291 0.5859 0.5756 0.6260 0.7346 0.6751 
LP3 0.7088 0.7342 0.5478 0.6612 0.5414 0.4959 0.7013 0.6891 0.6903 
LP1 0.7230 0.7433 0.6270 0.7668 0.6288 0.5601 0.7028 0.7448 0.7787 
10 
ChiSq 0.7394 0.7184 0.5846 0.8201 0.6346 0.5530 0.7273 0.7293 0.7329 
SLR 0.7424 0.7354 0.6166 0.7840 0.6285 0.5885 0.6352 0.7202 0.7424 
LP3 0.7369 0.7315 0.5532 0.7109 0.5548 0.4904 0.7284 0.6900 0.6907 
LP1 0.7118 0.7058 0.6137 0.8372 0.6371 0.5711 0.7282 0.7329 0.7622 
50 
ChiSq 0.7060 0.6438 0.5372 0.5643 0.5796 0.5263 0.6107 0.6562 0.5707 
SLR 0.7264 0.6970 0.5874 0.6568 0.6027 0.5774 0.5852 0.6841 0.7258 
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LP3 0.7519 0.7151 0.5219 0.5860 0.5314 0.5060 0.6398 0.6678 0.6071 
LP1 0.6694 0.6264 0.5348 0.6254 0.5791 0.5684 0.6377 0.6704 0.5804 
100 
ChiSq 0.6574 0.6034 0.5300 0.5368 0.5950 0.5362 0.5884 0.5905 0.5611 
SLR - 0.6874 0.5742 0.5993 0.6188 0.5671 0.5719 0.6639 0.6671 
LP3 0.7286 0.7154 0.5190 0.5420 0.5146 0.4921 0.5946 0.6301 0.5773 
LP1 0.6473 0.5862 0.5328 0.5452 0.5872 0.5391 0.6009 0.6054 0.5614 
 
A moderately predictive genetic signal is found in each dataset, with peak AUCs ranging 
from 0.62 to 0.83. The LP1 algorithm is comparable with the chi squared and SLR algorithms, 
outperforming either one in select cases. The LP1 algorithm is an improvement over the LP3 
algorithm. LP3 does only slightly worse than LP1 on some datasets, but fails to improve on 
random classification for the BD, CD, and HT datasets. The SLR method selects 500 or fewer 
variants in each dataset, showing good classification performance over its operable region. 
However, SLR is somewhat slower to increase AUC as the number of features increases, 
sometimes requiring 2-5 features to move beyond random classification, while the other 
algorithms tend to select predictive variants in the top 2. 
To statistically compare the predictive performance of the different algorithms, I 
computed the paired Wilcoxon signed-rank test over the GWAS AUCs. For each algorithm I 
used two rows of AUCs from Table 6 (two different feature selection thresholds for all 9 
datasets), yielding 18 AUC samples over which to compare algorithms. Two feature selection 
thresholds were used in order to increase sample size enough to have a meaningful p-value, even 
though the AUCs are not totally independent from one feature selection threshold to another. I 
examined feature selection thresholds of 5 and 10 SNPs (Table 7), as well as 50 and 100 SNPs 
(Table 8). These represent characteristic regions when using few SNVs, and when using a 
moderate number of SNPs. A large number of SNPs (i.e., 500 and 1000 SNPs) was not 
examined, because all algorithms tested tend to have diminishing performance in this range. 
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Below are all pairwise Wilcoxon comparisons, with the better-performing algorithm listed in 
each case along with the p-value of the comparison result. 
 
Table 7- Wilcoxon signed-ranked test p-value comparing AUCs of algorithms over 9 GWAS datasets for 
feature selection thresholds of 5 and 10. 
 ChiSq SLR LP3 
SLR ChiSq (p=0.00906) - - 
LP3 ChiSq (p=0.00124) LP3 (p=0.06432) - 
LP1 LP1 (p=0.00596) LP1 (p=0.00906) LP1(p=0.00096) 
 
 
Table 8 - Wilcoxon signed-ranked test p-value comparing AUCs of algorithms over 9 GWAS datasets for 
feature selection thresholds of 50 and 100. 
 ChiSq SLR LP3 
SLR SLR (p=0.0035) - - 
LP3 ChiSq (p=0.1096) SLR (p=0.00096) - 
LP1 LP1 (p=0.01108) SLR (p=0.01782) LP1 (p=0.00528) 
 
For small feature set sizes, the LP1 algorithm outperforms all other algorithms by a 
significant margin. The chi squared algorithm has the next-best performance, outperforming the 
SLR and LP3 methods. The SLR algorithm has the worst performance when using only 5 or 10 
features, but is not significantly different from LP3. When using 50 or 100 features, however, the 
SLR method performs the best by a significant margin. The LP1 algorithm outperforms all other 
methods besides SLR when using a larger feature set size. However, when correcting for 
multiple testing, LP1 is not significantly different from the chi squared test or SLR in the 50 to 
100 feature range. 
In addition to performing feature selection and classification on each dataset individually, 
I also performed cross-dataset experiments for the LOAD datasets. In these experiments, I 
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filtered both LOAD datasets to the same set of 64,984 SNPs, then selected features on one 
dataset and used the features to construct a classifier on the other dataset. The results are shown 
in Table 9. 
 
Table 9 - Prediction AUCs from selecting features on one LOAD dataset and predicting on the other. 
Dataset # SNPs Method 
Number of SNPs used in classifier 
1 2 5 10 50 100 500 1000 
TGen 
 
(Feature 
selection 
from 
ADRC) 
64,984 
(ADRC 
overlap, 
chr1-22) 
Chi Sq 0.6086 ±0.0294  
0.6863 
±0.0280 
0.7099 
±0.0270 
0.6958 
±0.0253 
0.6563 
±0.0286 
0.6097 
±0.0296 
0.5593 
±0.0310 
0.5563 
±0.0308 
SWRF 0.5952 ±0.0296 
0.6980 
±0.0274 
0.6994 
±0.0272 
0.7005 
±0.0274 
0.6756 
±0.0284 
0.6677 
±0.0284 
0.5635 
±0.0306 
0.5195 
±0.0310 
SLR 0.6086 ±0.0294 
0.6863 
±0.0280 
0.7164 
±0.0269 
0.7289 
±0.0263 
0.6522 
±0.0292 
0.6084 
±0.0300 - - 
LP3 0.5023 ±0.0306 
0.6039 
±0.0300 
0.7023 
±0.0272 
0.7037 
±0.0274  
0.6888 
±0.0276 
0.6543 
±0.0286 
0.6114 
±0.0298 
0.5690 
±0.0306 
LP1 0.6086 ±0.0294  
0.6863 
±0.0280 
0.7069 
±0.0271 
0.7058 
±0.0256 
0.6643 
±0.0276 
0.6497 
±0.0270 
0.5893 
±0.0299 
0.5443 
±0.0307 
ADRC 
 
(Feature 
selection 
from 
TGen) 
64,984 
(TGen 
overlap, 
chr1-22) 
Chi Sq 0.6172 ±0.0231 
0.6385 
±0.0229 
0.7419 
±0.0204 
0.7362 
±0.0208 
0.6695 
±0.0225 
0.6479 
±0.0227 
0.5396 
±0.0239 
0.5259 
±0.0122 
SWRF 0.5397 ±0.0239 
0.5345 
±0.0241 
0.5350 
±0.0241 
0.5401 
±0.0243 
0.5042 
±0.0243 
0.5257 
±0.0241 
0.5201 
±0.0241 
0.5053 
±0.0241 
SLR 0.5397 ±0.0214 
0.7006 
±0.0214 
0.7003 
±0.0214 
0.7048 
±0.0216 
0.6048 
±0.0233 
0.5854 
±0.0237 - - 
LP3 0.5397 ±0.0239 
0.6021 
±0.0235 
0.7283 
±0.0210 
0.7366 
±0.0208 
0.6853 
±0.0220 
0.6598 
±0.0225 
0.5678 
±0.0239 
0.5306 
±0.0239 
LP1 0.6172 ±0.0231 
0.6385 
±0.0229 
0.7422 
±0.0203 
0.7364 
±0.0206 
0.6702 
±0.0218 
0.6479 
±0.0227 
0.5377 
±0.0236 
0.5264 
±0.00241 
 
The results on the cross-dataset experiments are very similar to the results when 
performing feature selection and classification on the same dataset. This indicates that the 
selected features have predictive power outside of each individual cohort, suggesting that the 
top-ranked features are indeed generalizable. 
5.1.3.2 Biological Validity 
The LP1 algorithm was applied to each GWAS dataset, and the top-ranked features were 
examined for biological validity. Due to the time required to manually validate each SNP, the 
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control algorithms’ results were generally only examined for the Alzheimer’s disease datasets. 
The chi squared algorithm was also evaluated on the CD and HT datasets. Table 10 summarizes 
the validation results, listing the number of SNPs having evidence of association in the literature 
for each dataset. 
Table 10 - Summary of literature validation results. 
Dataset Algorithm SNPs validated (% precision) 
TGen 
Chi Sq 6 (24%) 
SWRF 5 (20%) 
SLR 7 (28%) 
LP3 14 (56%) 
LP1 11 (44%) 
ADRC 
Chi Sq 10 (40%) 
SWRF 2 (8%) 
SLR 5 (20%) 
LP3 10 (40%) 
LP1 12 (48%) 
BD LP1 17 (68%) 
CAD LP1 11 (44%) 
CD Chi Sq 20 (80%) LP1 19 (76%) 
HT Chi Sq 9 (36%) LP1 12 (48%) 
RA LP1 11 (44%) 
T1D LP1   7 (28%) 
T2D LP1 15 (60%) 
Total LP1 108 (48%) 
 
The LP1 algorithm returned many biologically validated SNPs, overall finding evidence 
for 48% of the 225 SNPs examined over the nine datasets. On the LOAD datasets, the LP1 and 
LP3 algorithms outperformed the control methods. Applying a z-test to compare proportions, 
LP3 significantly outperforms ChiSq, SWRF and SLR on the TGen dataset, and LP1 
significantly outperforms SWRF and SLR on the ADRC dataset. On the CD and HT datasets, the 
LP1 method is statistically equivalent to the chi squared algorithm, and in fact returns many of 
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the same top-ranked SNPs. Below are the top 25 SNPs as ranked by LP1 for each dataset (Table 
11 through Table 19). The control algorithms’ results are given in Appendix B. 
Table 11 - Top 25 SNPs for TGen using LP1 (α = 0.25). 
Rank rsID Chr Gene Notes 
1 rs429358 19 APOE APOE risk allele determined by  rs7412 and rs429358 [53] 
2 rs4420638 19 APOC In strong linkage disequilibrium with APOE SNPs [54] 
3 rs7412 19 APOE APOE risk allele determined by  rs7412 and rs429358 [53] 
4 rs10824310 10 PRKG1 Significant association with LOAD [55] 
5 rs7079348 10 C10orf11 - 
6 rs3732443 3 GXYLT2 - 
7 rs582790 11 - - 
8 rs934745 18 MAPK4 - 
9 rs7964760 12 NAV3 NAV3 mRNA levels elevated in AD brains [56] 
10 rs16974268 15 SLCO3A1 - 
11 rs10499687 7 VWC2 - 
12 rs6717497 2 - - 
13 rs17330779 7 NRCAM Associated with axonal degeneration in LOAD [57] 
14 rs3007246 13 - - 
15 rs7077757 10 RBM20 Meta-analysis of multiple studies showed association [58] 
16 rs12162084 16 - Significant association with LOAD [59] 
17 rs3905173 1 - Associated in Bayesian analysis of TGen data [60] 
18 rs17048190 2 - - 
19 rs2968848 7 - - 
20 rs12041702 1 - - 
21 rs9934599 16 IL34 - 
22 rs950922 1 ALPL - 
23 rs10115381 9 - - 
24 rs1038891 11 LRRC4C SNP associated with LOAD in genome-wide analysis [61] 
25 rs9398855 6 THEMIS Possible gene association via GAB2 pathway [62] 
 
Table 12 - Top 25 SNPs for ADRC using LP1 (α = 0.25). 
Rank rsID Chr Gene Notes 
1 rs439401 19 APOE In strong LD with rs7412 and rs429358 [63] 
2 rs5157 19 APOC4 In strong LD with other APOC risk SNPs [64] 
3 rs157582 19 TOMM40 Showed LOAD association in African-American cohort [65] 
4 rs2075650 19 APOE4 Predictive of longevity of LOAD patients [66, 67] 
5 rs445925 19 - Located between APOE and APOC genes [68] 
6 rs8106922 19 TOMM40 Meta-analysis finds significant association with LOAD [69] 
7 rs11076978 16 - - 
8 rs405509 19 APOE APOE promoter varies LOAD risk [70] 
9 rs157580 19 TOMM40 Associated with LOAD in Chinese population [71] 
10 rs3738269 1 IGFN1 - 
11 rs832156 1 IGFN1 - 
12 rs12507679 4 STAP1 - 
13 rs26845 16 ECI1 - 
14 rs13132585 4 STAP1 - 
15 rs17428956 1 - - 
16 rs10994553 10 - - 
17 rs9909412 17 COX10 Gene differentially expressed in LOAD patients [72] 
18 rs206081 13 BRCA2 - 
19 rs4558873 4 SORCS2 Gene differentially expressed in LOAD patients [73] 
20 rs151716 1 - - 
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21 rs12140610 1 - - 
22 rs9487940 6 - - 
23 rs279877 9 DMRT3 CNV in related DMRT1 gene associated with LOAD [74] 
24 rs537761 1 - - 
25 rs8082842 18 RAB31 Gene involved in potential treatment [75] 
 
Table 13 - Top 25 SNPs for BD using LP1 (α = 0.25). 
Rank rsID Chr Gene Notes 
1 rs1909936 8 - Significant in RF analysis of WTCCC [76] 
2 rs7653441 3 FNDC3B Significant association in independent cohort [77] 
3 rs6577370 1 - - 
4 rs17116117 11 HTR3B Gene mutations disrupts serotonin regulation [78] 
5 rs12355606 10 CACNB2 Associated in Han Chinese population [79] 
6 rs1442650 18 LINC00907 - 
7 rs12938916 17 - Discovered in nonparametric analysis of WTCCC data [80] 
8 rs7260296 19 - - 
9 rs11059460 12 - - 
10 rs420259 16 PALB2 SNP associated with BD in Scandinavian cohort [81] 
11 rs2837588 21 DSCAM Gene associated with BD  [82] 
12 rs858719 11 ZBTB44 Significant in WTCCC study [83] 
13 rs914715 11 ZBTB44 Significant in WTCCC study [83] 
14 rs2953146 2 RNPEPL1 Significant in WTCCC study [83] 
15 rs16857512 1 CACNA1E Gene implicated in treatment efficacy [84] 
16 rs514636 3 LAMP3 Discovered in secondary analysis of WTCCC [80] 
17 rs2683780 3 - - 
18 rs6458307 6 - BD association discovered in Finnish population [85] 
19 rs6414500 3 LAMP3 Discovered in secondary analysis of WTCCC [80] 
20 rs6414498 3 LAMP3 Discovered in secondary analysis of WTCCC [80] 
21 rs12472797 2 - - 
22 rs12980129 19 - Discovered as part of epistatic interactions in WTCCC data [86] 
23 rs7152966 14 - - 
24 rs9318400 13 - - 
25 rs682970 10 CELF2 Gene associated with major depression [87] 
 
Table 14 - Top 25 SNPs for CAD using LP1 (α = 0.25). 
Rank rsID Chr Gene Notes 
1 rs4799934 16 PALB2 - 
2 rs7906587 10 PNLIPRP3 Gene associated with mean arterial pressure [88] 
3 rs11671119 19 MEF2BNB-
MEF2B 
Gene associated with cardiac development [89] 
4 rs17042882 3 PLCL2 Gene expression modified by cardiovascular disease  risk reduction therapy [90] 
5 rs159171 5 - - 
6 rs16955238 16 - - 
7 rs16891338 8 SAMD12-AS1 - 
8 rs16908145 8 FLJ45872 - 
9 rs6989092 8 - - 
10 rs16883114 8 - - 
11 rs7653441 3 FNDC3B Locus associated with heart rate and rhythm disorders [91]  
12 rs4970605 1  Interaction found in WTCCC study [92] 
13 rs17022496 4 BMPR1B - 
14 rs12724674 1 - - 
15 rs1333049 9 - Replicated in German, Japanese and Korean populations  [93, 94] 
16 rs9884478 4 NPFFR2 - 
17 rs17146094 7 EIF4H Discovered in exhaustive epistatic analysis of WTCCC data [95] 
18 rs906766 3 MED12L - 
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19 rs7002837 8 - - 
20 rs17672135 1 FMN2 SNP discovered in independent experiments [96, 97]  
21 rs4846770 1 MIA3 Meta analysis implicated gene [98] 
22 rs326296 3 - - 
23 rs6490506 13 ZMYM2 - 
24 rs523096 9 CDKN2B-AS1 WTCCC gene replicated in independent German cohort [93] 
25 rs518394 9 CDKN2B-AS1 WTCCC gene replicated in independent German cohort [93]  
 
Table 15 - Top 25 SNPs for CD using LP1 (α = 0.25). 
Rank rsID Chr Gene Notes 
1 rs17116117 11 HTR3B - 
2 rs10483456 14 RALGAPA1 Associated with CD in independent study of Chinese individuals [99] 
3 rs11209026 1 IL23R Association found in multiple studies [100, 101] 
4 rs2076756 16 NOD2 Associated in independent study [102]  
5 rs10210302 2 ATG16L1 Defects in gene cause susceptibility to IBD, sex-related risk for CD [103] 
6 rs6752107 2 ATG16L1 Defects in gene cause susceptibility to IBD, sex-related risk for CD [103]  
7 rs6431654 2 ATG16L1 Defects in gene cause susceptibility to IBD, sex-related risk for CD [103] 
8 rs3828309 2 ATG16L1 Defects in gene cause susceptibility to IBD, sex-related risk for CD  [103, 
104]  
9 rs17234657 5 - WTCCC finding replicated in independent cohorts [105, 106]  
10 rs2066843 16 NOD2 Associated with CD in independent study [102] 
11 rs3792106 2 ATG16L1 Defects in gene cause susceptibility to IBD, sex-related risk for CD [103, 104] 
12 rs11805303 1 IL23R IL23 implicated in CD [107]  
13 rs11957215 5 - - 
14 rs9292777 5 - WTCCC SNP replicated in independent study [108] 
15 rs17221417 16 NOD2 NOD2 implicated in CD [102] 
16 rs10489629 1 IL23R Replicated in multiple studies [102, 109, 110]  
17 rs2201841 1 IL23R SNP implicated in distinct populations [111] 
18 rs4957295 5 - - 
19 rs10213846 5 - - 
20 rs6871834 5 - - 
21 rs4957297 5 - Replicated independent of WTCCC [112] 
22 rs4957300 5 - - 
23 rs16869934 5 - Discovered in BIC analysis of WTCCC [113] 
24 rs12119179 1 - Associated with a disease with similar genetic profile  [114] 
25 rs11209033 1 - Cited in patent for testing for autoimmune-associated polymorphisms [115] 
 
Table 16 - Top 25 SNPs for HT using LP1 (α = 0.25). 
Rank rsID Chr Gene Notes 
1 rs4765066 12 - - 
2 rs488101 9  Associated with arterial plaque [116] 
3 rs4867173 5 - - 
4 rs11782342 8 KCNB2 Discovered as part of epistatic interactions in WTCCC data [86] 
5 rs11024327 11 OTOG Found in combined analysis of WTCCC data [117] 
6 rs16857512 1 CACNA1E Calcium gate channels implicated in BP regulation [118] 
7 rs2820037 1 - SNP associated with BP regulation [119] 
8 rs2790622 1 - - 
9 rs2820038 1 - - 
10 rs6574988 14 - - 
11 rs2820046 1 - - 
12 rs16945811 17 YWHAE Gene implicated in HT [120] 
13 rs9428826 1 - - 
14 rs2398162 15 NR2F2-AS1 Population-specific association has been replicated [121] 
15 rs2820026 1 - - 
16 rs921535 15 - - 
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17 rs17018584 4 CCSER1 SNP associated with heart disease in rats and humans[122] 
18 rs10889923 1 NEGR1 - 
19 rs1022684 20 SEC23B - 
20 rs2191003 4 - - 
21 rs41515647 1 ST6GALNAC5 Gene associated with heart disease [123] 
22 rs300916 4 GAB1 Discovered in combined WTCCC + Australian cohort [117] 
23 rs1935683 6 - - 
24 rs13119672 4 PPARGC1A Gene associated with HT [124] 
25 rs17201619 17 - Discovered in combined WTCCC + Australian cohort [117] 
 
Table 17 - Top 25 SNPs for RA using LP1 (α = 0.25) 
Rank rsID Chr Gene Notes 
1 rs4718582 7 - - 
2 rs12670243 7 - - 
3 rs9271850 6 - SNP associated in Swedish study [125] 
4 rs17104722 14 - - 
5 rs6679677 1 PHTF1 Approached significance in low-power, independent study [126] 
6 rs1733717 10 MBL2 SNP associated with risk of RA [127] 
7 rs1369036 1 - - 
8 rs3129768 6 - - 
9 rs2282859 6 FGFR1OP - 
10 rs1230666  - - 
11 rs9272346 6 HLA-DQA1 Gene implicated in Taiwanese population [128] 
12 rs1711029 15 - - 
13 rs2943570 8 - - 
14 rs16874205 8 - Replicated in Spanish population [129] 
15 rs2488457 1 PTPN22 Replicated in Caucasian but not Korean population[130]  
16 rs11776005 8 - - 
17 rs1028850 13 LINC00598 - 
18 rs10834744 11 ART1 - 
19 rs9272723 6 HLA-DQA1 Gene implicated in Taiwanese population [128] 
20 rs1217396 1 RSBN1 Marginal association found in independent cohort [131] 
21 rs1230649 1 PHTF1 - 
22 rs1230658 1 MAGI3 Gene associated with RA [132] 
23 rs1217200 1 MAGI3 Gene associated with RA [132] 
24 rs1562694 14 - - 
25 rs2837960 21 - Validated in independent study [133] 
 
Table 18 - Top 25 SNPs for T1D using LP1 (α = 0.25) 
Rank rsID Chr Gene Notes 
1 rs9272346 6 HLA-DQA1 Associated in WTCCC data [83] 
2 rs3129768 6 - - 
3 rs6679677 1 PHTF1 Associated with T1D, may be in strong LD with causal variant [134] 
4 rs17116117 11 HTR3B - 
5 rs9989228 14 MIPOL1 - 
6 rs17696736 12 NAA25 In LD with possible causal SNPs, validated in independent cohort [135] 
7 rs11171739 12 - In LD with possible causal SNPs, validated in independent cohort [135] 
8 rs10483456 14 RALGAPA1 - 
9 rs6894569 5 - - 
10 rs765534 11 - - 
11 rs1977 6 BTN3A2 Multilocus analysis implicated gene [136] 
12 rs9358932 6 - - 
13 rs7745603 6 - - 
14 rs10494787 1 FLJ43585 - 
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15 rs9393713 6 BTN3A2 Multilocus analysis implicated gene [136] 
16 rs2237236 6 BTN3A3 - 
17 rs1873914 12 RAB5B - 
18 rs1343125 1 MAGI3 - 
19 rs9393848 6 - - 
20 rs9468203 6 - - 
21 rs3734536 6 BTN3A2 - 
22 rs7776351 6 - - 
23 rs4711165 6 ZKSCAN8 - 
24 rs12708716 16 CLEC16A Gene associated with T1D, SNP discovered in WTCCC [137] 
25 rs17711344 6 - - 
 
Table 19 - Top 25 SNPs for T2D using LP1 (α = 0.25) 
Rank rsID Chr Gene Notes 
1 rs3777582 6 CLIC5 - 
2 rs11042656 11 SBF2 - 
3 rs1477523 7 AC009264.1 Linked to T2D through HDL regulation [138]  
4 rs17116117 11 HTR3B - 
5 rs17117531 15 - - 
6 rs10492267 12 - Found in Bayesian analysis of WTCCC data[139] 
7 rs4506565 10 TCF7L2 Validated in multiple distinct populations [140-142]  
8 rs10483456 14 RALGAPA1 Linked to T2D through HDL regulation [138] 
9 rs7193144 16 FTO Validated in Indian population [143, 144] 
10 rs9405484 6 LOC102723944 - 
11 rs9939609 16 FTO Replicated in Norwegian population [145] 
12 rs7917983 10 TCF7L2 Validated in Indian population [146, 147] 
13 rs13373826 1 SLC44A5 SNP associated with T2D [148] 
14 rs1025450 18 - - 
15 rs7901275 10 TCF7L2 Discovered in independent study [149] 
16 rs9926289 16 FTO Associated with obesity Polish population [150] 
17 rs9465871 6 CDKAL1 Validated in Chinese population [151] 
18 rs9939973 16 FTO Implicated in obesity [152] 
19 rs9940128 16 FTO Linked to T2D in Indian population [153] 
20 rs9367532 6 - - 
21 rs1121980 16 FTO Validated in Swedish population [154] 
22 rs1957779 14 RHOJ - 
23 rs9930506 16 FTO Implicated in obesity [152] 
24 rs358806 3 - - 
25 rs903228 2 - - 
5.1.3.3 Computational Efficiency 
The LP1 algorithm is no more computationally complex than the original LP3 algorithm, 
requiring only a single extra iteration of propagation to collect the soft labels in a contingency 
table, and is O(kNd). The SLR algorithm’s computational complexity is at least O(N2d), 
stemming from the matrix inversions necessary to compute the regression coefficients. The chi 
squared algorithm is simply O(Nd). All algorithms were benchmarked on one fold of the BD 
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WTCCC data, running on a 2.33 GHz processor with 8GB of RAM available and excluding time 
required to read in the data files. The chi squared test ran the fastest, in about 11 minutes. The 
SLR method was slowest, taking nearly 3 days to complete. The LP1 method ran fairly quickly 
for a multivariate algorithm, requiring 42 minutes. The SWRF method was not applied to the 
large-scale GWAS datasets, in light of the fact that the increased sample size would have 
increased the computation time to at least several weeks for a single fold. 
5.1.3.4 Feature Reproducibility on LOAD data 
For the ranking reproducibility experiments, I filtered the two LOAD datasets so they contain 
only the intersection of the features. There are 64,984 SNPs in common between the two datasets 
which were ranked by each algorithm, and the intersection of these rankings is compared. 
 Figure 9 shows the reproducibility results on the LOAD datasets. Chi squared identifies 
the first few SNPs reproducibly; these are SNPs that are located in genes apolipoprotein-E 
(APOE) and apolipoprotein-C (APOC) and are known to have large effects sizes. Beyond the 
first few SNPs, however, the reproducibility of chi squared drops rapidly to a level which is 
effectively random. The SWRF algorithm produces results that are no better than random for the 
genome-wide datasets. The implicitly selective SLR method is not shown on this graph because 
only two features overlap in the selected subset, yielding virtually no reproducibility. 
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 Figure 9 - Reproducibility curves of top-ranked features with 95% confidence envelope. 
The x-axis shows the fraction of top-ranked features being considered, and the y-axis shows the fraction 
of features in common to rankings obtained from each of the two datasets independently (TGen and ADRC). For 
this plot, the chi squared and SWRF methods are virtually indistinguishable from the random performance curve 
along the diagonal. 
LP1, in contrast to these two methods, shows good reproducibility for many of the top-
ranked SNPs, and does so even in the high-dimensional datasets. The algorithm has low 
reproducibility for the first few SNPs but quickly surpasses chi squared and SWRF. 
5.2 EVALUATION OF LP1 WITH PRIOR KNOWLEDGE 
This section presents the results of the experiments on the second algorithmic extension 
described in 3.4.2.2. Two methods of incorporating knowledge were initially proposed: an edge 
weighting method and a prior pseudocount method. After numerous experiments with the edge 
weighting method, it was ultimately found to be ineffective. Even drastic changes in the network 
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edge weights had little impact on the final LP1 score. SNP rankings remained virtually 
unchanged, with only miniscule changes to SNP p-value scores. It appears the edge weights do 
not have enough impact on the labeling of the sample nodes, from which the LP1 score is 
directly computed. By changing the weight of all edges connecting to a particular SNP 
identically, the overall proportion of signal coming from cases or controls remains unchanged. 
One solution might be to have differential weighting of cases versus controls for SNPs with a 
prior likelihood of association. This would require knowledge (or assumption) of the genetic 
model underlying the association. 
The prior pseudocount method, in contrast, resulted in promising changes to the rankings. 
Prior knowledge experiments were performed on the synthetic, semi-synthetic, and 
GWASdatasets. For the GWAS datasets, I used GERP and MAF prior knowledge scores 
corresponding to the SNPs in the data. For the synthetic dataset, the variables have no biological 
meaning, so I instead used a “gold standard” prior knowledge. This prior gives the maximum 
prior to the 35 true causal variants, and a null prior to all other variants. The semi-synthetic 
dataset contains real SNPs, but the phenotypic model does not take into account evolutionary 
conservation. Because of this, I use a gold standard prior which upweights the 72 true causal 
SNVs, as well as the MAF prior. The use of gold standard priors is useful for testing the 
algorithmic validity of the method, because the prior values are known to correspond to 
meaningful variants. For the GWAS datasets, a lack of good performance could either be a result 
of an invalid method, or an invalid prior. By ensuring valid priors, we can test the 
appropriateness of the pseudocount method. 
Figure 10 shows the results of the prior knowledge experiments on the synthetic dataset, 
for increasing prior equivalent sample size (PESS). When PESS=0, the LP1 algorithm does not 
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use any prior information and is equivalent to the original LP1 algorithm. As the PESS increases, 
the algorithm’s ability to recovery the causal variants increases as well. The PESS of 1000 at 
first glance appears worse than the PESS of 100, but in fact has better performance in the low-
precision tail region, recovering more of the rare variants as evidenced by the better ROC 
performance.  
 
Figure 10 - Precision-recall and ROC curves for prior knowledge experiments on synthetic data. 
 
Similar results are found on the semi-synthetic GAW17 dataset. The LP1 algorithm with 
PESS = 0 does especially poorly on this dataset, showing difficulty in discovering the rare causal 
SNPs. A small to moderate PESS of up to 1000 yields marginal improvement in the algorithm’s 
performance. The sample size for the GAW17 is larger than the synthetic dataset, and requires a 
larger PESS values for improved performance. 
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 Figure 11 - Precision-recall and ROC curves for prior knowledge experiments on semi-synthetic data 
using gold standard prior knowledge. 
The GAW17 data was also analyzed using the MAF prior, with the knowledge that many 
of the causal SNVs in the model are very rare. The MAF prior does not significantly improve 
LP1’s performance on the GAW17 data, and in fact shows decrease performance for large PESS. 
The MAF prior’s failure could be explained by the fact that not all SNVs in the causal model are 
the rarest variants, and also that rare SNVs which appear in only one individual (about 40% of 
the variants) are all given the exact same upweighting, making it difficult to distinguish among 
them. 
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 Figure 12 - Precision-recall and ROC curves for prior knowledged experiments on semi-synthetic 
data using MAF prior. 
The prior knowledge method was applied to the GWAS datasets using both GERP and 
MAF priors in place of the gold standard priors used in the synthetic and semi-synthetic 
experiments. I tested a PESS of 50 and 500, and the classification AUC results are given in Table 
20 for feature set sizes between 5 and 100. The full set of results with 95% confidence intervals 
is given in Appendix A. 
Table 20 - Prior knowledge AUCs for nine GWAS datasets. 
Features Algorithm Dataset TGen ADRC BD CAD CD HT RA T1D T2D 
5 
LP1 0.7230 0.7433 0.6270 0.7668 0.6288 0.5601 0.7013 0.7448 0.7787 
LP1+ 
GERP50 0.7228 0.7433 0.6270 0.7668 0.6236 0.5625 0.7028 0.7445 0.7739 
LP1+ 
GERP500 0.5112 0.5043 0.5108 0.7489 0.5085 0.4946 0.6005 0.7093 0.7320 
LP1+ 
MAF50 0.7014 0.7345 0.6160 0.7502 0.6212 0.5522 0.6969 0.7445 0.7669 
LP1+ 
MAF500 0.5102 0.5068 0.5111 0.7023 0.5065 0.5002 0.5985 0.6875 0.6255 
10 
LP1 0.7118 0.7058 0.6137 0.8372 0.6371 0.5711 0.7284 0.7329 0.7622 
LP1+ 
GERP50 0.7145 0.7102 0.6131 0.8372 0.6358 0.5715 0.7282 0.7306 0.7551 
LP1+ 
GERP500 0.5108 0.5138 0.5118 0.8063 0.5465 0.4742 0.6654 0.7040 0.7573 
LP1+ 
MAF50 0.6983 0.7001 0.6034 0.8361 0.6316 0.5604 0.7118 0.7296 0.7485 
LP1+ 
MAF500 0.5129 0.5264 0.5118 0.7356 0.5115 0.4841 0.6254 0.6755 0.6548 
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50 
LP1 0.6694 0.6264 0.5348 0.6254 0.5791 0.5684 0.6398 0.6704 0.5804 
LP1+ 
GERP50 0.6587 0.6133 0.5376 0.5950 0.5870 0.5430 0.6377 0.6624 0.5703 
LP1+ 
GERP500 0.5145 0.5057 0.5037 0.5903 0.5046 0.4987 0.5914 0.6383 0.5715 
LP1+ 
MAF50 0.6455 0.6023 0.5485 0.6055 0.5901 0.5497 0.6291 0.6544 0.5693 
LP1+ 
MAF500 0.5123 0.5148 0.5024 0.5842 0.5048 0.4964 0.5724 0.6212 0.5685 
100 
LP1 0.6478 0.5862 0.5328 0.5452 0.5872 0.5391 0.5946 0.6054 0.5614 
LP1+ 
GERP50 0.6426 0.5789 0.5278 0.5514 0.5805 0.5364 0.6009 0.5983 0.5640 
LP1+ 
GERP500 0.5088 0.5102 0.5095 0.5307 0.5073 0.4905 0.5698 0.6077 0.5455 
LP1+ 
MAF50 0.6326 0.5643 0.5153 0.5489 0.5640 0.5456 0.6015 0.5838 0.5542 
LP1+ 
MAF500 0.5101 0.5089 0.5084 0.5267 0.5013 0.4921 0.5448 0.6014 0.5326 
 
For PESS = 50, the downstream classification performance is diminished, but not 
significantly. The PESS of 500, however, is a severe detriment to the classification performance. 
On some datasets, the prior masks the true genomic signal, leading to poor feature selection and 
essentially random classification. For some datasets, the PESS of 500 results in a moderate drop 
in AUC, but does not completely mask the genomic signal. 
To statistically compare the performance of the prior method on GWAS data, I computed 
the paired Wilcoxon signed-rank test over the GWAS AUCs. Using each of the nine GWAS 
datasets, I used two rows of the AUCs in Table 20 (corresponding to two different feature 
selection thresholds), yielding 18 paired AUC samples over which to compare algorithms. Below 
are the pairwise Wilcoxon comparisons with the better-performing algorithm listed in each case 
along with the p-value of the comparison result. 
Table 21 - Wilcoxon signed-ranked test p-value comparing AUCs of algorithms over 9 GWAS 
datasets for feature selection thresholds of 5 and 10. 
 LP1 LP1+GERP50 LP1+GERP500 LP1+MAF50 
LP1+GERP50 LP1 (p = 0.2801) - - - 
LP1+GERP500 LP1 (p = 0.0002) LP1+GERP50  (p = 0.0002) - 
- 
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LP1+MAF50 LP1 (p = 0.0002) LP1+GERP50 (p = 0.003) 
LP1+MAF50 
(p = 0.0002) 
- 
LP1+MAF500 LP1 (p = 0.0002) LP1+GERP50 (p = 0.0002) 
LP1+GERP500 
(p = 0.0548) 
LP1+MAF50 
(p = 0.0002) 
 
 
Table 22 - Wilcoxon signed-ranked test p-value comparing AUCs of algorithms over 9 GWAS datasets for 
feature selection thresholds of 50 and 100. 
 LP1 LP1+GERP50 LP1+GERP500 LP1+MAF50 
LP1+GERP50 LP1 (p = 0.0155) - - - 
LP1+GERP500 LP1 (p = 0.0002) LP1+GERP50 (p = 0.0005) - 
- 
LP1+MAF50 LP1 (p = 0.0278) LP1+GERP50 (p = 0.2501) 
LP1+MAF50 
(p = 0.001) 
- 
LP1+MAF500 LP1 (p = 0.0002) LP1+GERP50 (p = 0.0002) 
LP1+GERP500 
(p = 0.0069) 
LP1+MAF50 
(p = 0.0003) 
 
The prior knowledge method performs significantly worse than the original LP1 
algorithm with no prior knowledge. A larger PESS value gives significantly worse performance 
than the smaller PESS value. This indicates either that a useful prior is not being used, or that it 
is being incorporated incorrectly. A discussion of possible causes and potential solutions can be 
found in Section 6.1.2. In addition, the GERP score generally outperforms the MAF when using 
the same PESS. 
5.3 EVALUATION OF LP1 WITH RANKING COMBINATION 
The ranking combination experiments combined the LP1 feature scores and ranks with the chi 
squared test’s scores and ranks, as well as SLR’s method’s ranks. The combination method was 
tested on the synthetic dataset and the GWAS datasets. The method was not tested on the 
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GAW17 semi-synthetic dataset, due to overall poor performance of each algorithm on this 
dataset. Figure 13Figure 13 shows the precision-recall and ROC results of the combination 
methods on the synthetic data. 
 
Figure 13 - Combination method results on synthetic data. 
The original LP1 method’s performance is almost indistinguishable the score-based 
combination with the chi squared test. The rank-based LP1+ChiSq method, in contrast, performs 
quite poorly. The LP1+SLR rank-based method also performs very similarly to the LP1 method. 
The results of the combination methods on the GWAS datasets are shown in Table 23 for 
5 through 100 features. The LP1+ChiSq score-based method once again has fairly similar results 
to the LP1 method alone. The rank based method does not change much for the first few feature 
set sizes (i.e. 1, 2, and 5), but leads to slightly diminished performance for larger feature sets. 
Compared to LP1, the LP1+SLR rank-based method had some diminished performance for small 
feature set sizes (where SLR performs poorly), but improved for larger feature sets (where SLR 
has the best performance). 
Table 23 - Prediction AUCs for combination methods on GWAS data. 
Features Algorithm Dataset TGen ADRC BD CAD CD HT RA T1D T2D 
5 LP1+ChiSq (score) 0.7230 0.7433 0.6150 0.7668 0.6259 0.5546 0.7013 0.7448 0.7783 
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LP1+ChiSq 
(rank) 0.7230 0.7233 0.6053 0.7501 0.6284 0.5501 0.7013 0.7448 0.7546 
LP1+SLR 
(rank) 0.7214 0.7433 0.6053 0.7504 0.6118 0.5661 0.7007 0.7418 0.7603 
10 
LP1+ChiSq 
(score) 0.7234 0.7111 0.6011 0.8118 0.6349 0.5670 0.7280 0.7301 0.7514 
LP1+ChiSq 
(rank) 0.6873 0.7027 0.6022 0.8007 0.6224 0.5529 0.7225 0.7316 0.7465 
LP1+SLR 
(rank) 0.7336 0.7244 0.6022 0.8016 0.6371 0.5802 0.7318 0.7311 0.7575 
50 
LP1+ChiSq 
(score) 0.6905 0.6361 0.5392 0.5718 0.5618 0.5407 0.6218 0.6700 0.5794 
LP1+ChiSq 
(rank) 0.6635 0.6254 0.5217 0.5525 0.5652 0.5548 0.6010 0.6702 0.5771 
LP1+SLR 
(rank) 0.7251 0.6518 0.5656 0.6548 0.6012 0.5715 0.6623 0.6819 0.6853 
100 
LP1+ChiSq 
(score) 0.6458 0.5915 0.5324 0.5540 0.5873 0.5391 0.5881 0.6045 0.5610 
LP1+ChiSq 
(rank) 0.6217 0.5619 0.5246 0.5314 0.5676 0.5307 0.5891 0.5984 0.5596 
LP1+SLR 
(rank) 0.6378 0.6152 0.5612 0.5228 0.6033 0.5642 0.6583 0.6547 0.6608 
 
To statistically compare the performance of the prior method on GWAS data, I computed 
the paired Wilcoxon signed-rank test over the GWAS AUCs. Using each of the nine GWAS 
datasets, I used two rows of AUCs from Table 23 (two different feature selection thresholds), 
yielding 18 paired AUC samples over which to compare algorithms. Below are the relevant AUC 
values across all datasets, followed by the pairwise Wilcoxon comparisons with the better-
performing algorithm listed in each case along with the p-value of the comparison result. 
Table 24 - Wilcoxon signed-ranked test p-value comparing AUCs of algorithms over 9 GWAS 
datasets for feature selection thresholds of 5 and 10. 
 LP1 LP1+ChiSq (score) LP1+ChiSq (rank) 
LP1+ChiSq 
(score) 
LP1 
(p = 0.0466) - - 
LP1+ChiSq 
(rank) 
LP1  
(p = 0.0006) 
LP1+ChiSq (score)  
(p = 0.0021) -- 
LP1+SLR 
(rank) 
LP1 
(p = 0.3030) 
LP1+SLR (rank) 
(p = 0.9282) 
LP1+SLR (rank) 
(p = 0.0384) 
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Table 25 - Wilcoxon signed-ranked test p-value comparing AUCs of algorithms over 9 GWAS datasets for 
feature selection thresholds of 50 and 100. 
 LP1 LP1+ChiSq (score) LP1+ChiSq (rank) 
LP1+ChiSq 
(score) 
LP1  
(p = 0.0687) - - 
LP1+ChiSq 
(rank) 
LP1 
(p = 0.0002) 
LP1+ChiSq (score)  
(p = 0.0032) - 
LP1+SLR 
(rank) 
LP1+SLR (rank)  
(p = 0.0037) 
LP1+SLR (rank)  
(p = 0.0002) 
LP1+SLR (rank)  
(p = 0.0012) 
 
The Wilcoxon tests show that the LP1+SLR rank-based method performed better for 
larger feature set sizes of 50 and 100, but does not outperform the LP1 method alone for smaller 
feature set sizes. For the LP1+ChiSq methods, the score-based method performed better than the 
rank-based method. 
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6.0  CONCLUSIONS AND FUTURE WORK 
In this dissertation, I developed and applied several extensions to label propagation (LP), a 
multivariate feature selection algorithm, with the goal of performing feature selection for 
biomarker discovery in GWAS SNP data. I implemented the LP algorithm as well as several 
extensions to tailor the method to genomic data. I applied these methods to synthetic, semi-
synthetic, and GWAS datasets and evaluated their performance in terms of precision-recall, 
predictive power, reproducibility, and biological validity. The LP1 extension was found to 
improve upon the original LP3 method under several conditions, namely, the ability to identify 
variants with population-wide predictive power. The prior knowledge incorporation methods did 
not significantly improve performance over not using prior knowledge, and the ranking 
combination method had limited success. A summary of the findings is presented in the next 
section followed by some directions for future work in the last section. 
6.1 CONTRIBUTIONS AND FINDINGS 
This section summarizes the main contributions and the findings of the research presented in this 
dissertation. 
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6.1.1 LP1 Extension 
On the synthetic data, the LP1 extension performed worse than the original LP3 method. The 
LP1 method was unable to identify rare variants, because the signal from just a few samples is 
being lost in the course of the population-wide contingency table analysis. In contrast, the LP3 
score for a SNP state is more or less independent of sample size, so even a variant with just a few 
occurrences in a population can get a highly ranked score. The synthetic experiments also 
provided support for using a value between 0 and 0.5 for the parameter α, limiting the amount of 
diffusion in the propagation graph. 
All algorithms performed poorly on the GAW17 data, stymied by the rarity of the causal 
variants and the complex phenotypic model. These experiments indicate that LP as formulated in 
this dissertation may not be well-suited to the discovery of rare SNVs. However, with the 
increasing sample sizes of genomic datasets, it is possible that rare variants will occur in large 
enough numbers for LP to be useful. 
Results of the LP1 algorithm on GWAS data showed that LP1 is an improvement over 
the original LP3 algorithm. By using the soft sample labels as pseudocounts, LP1 computes a 
population-wide score that is not specific to a particular SNP allele. This score ranks a SNP 
highly only if there is a significant amount of data to support the association, and is not 
susceptible to highly-ranked rare variants that are not predictive on a population scale.  
While the LP1 method is effective at finding common predictive variants, it showed reduced 
power in finding the rare causal variants in the synthetic dataset. 
The LP1 algorithm had good performance in selecting SNPs that could be validated in the 
literature, finding evidence for nearly half of the top-ranked 25 SNPs across all GWAS datasets. 
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The other top-ranked SNPs that were not validated are good candidates for further study to 
uncover possible mechanisms of association with disease. 
6.1.2 Prior Knowledge 
The edge weighting method of incorporating prior knowledge was found to be ineffective. This 
could be a result of the LP1 score utilizing the sample node scores directly in the contingency 
table analysis. Because the sample nodes begin with labels, they are relatively inflexible when 
the diffusion parameter α is low. Referring back to the iterative update equations, it can be seen 
that the current label on a node is a linear combination of the initial label and the currently labels 
on from the other side of the network. With α less than 0.5, the initial labeling dominates, and in 
fact, cannot be overcome by contributions from the other side of the network. That is, a node 
with an initial label of +1 will ultimately have a positive score no matter what the network 
geometry and labeling, and similarly a node with an initial label of -1 will always finish with a 
negative score.  
In the course of experimentation, I found a low α of 0.25 to be very effective. Under this 
parameterization, a labeled node will not change class from +1 to -1, despite being given an 
updated soft labeling. Unlabeled nodes still have flexibility to drift positive or negative, within a 
limited range around 0. It seems that the edge weight prior knowledge method simply does not 
have enough effect on the relabeling of the initially labeled sample nodes to impact the final LP1 
score. 
In contrast, the prior pseudocount method had a marked effect on the feature ranking. The 
utility of the method was shown on the synthetic and semi-synthetic datasets. The gold standard 
prior increased LP1’s precision and recall, especially when using a large PESS. The prior method 
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results on the GWAS datasets were less promising, having no significant impact on the 
downstream classification accuracy for small values of PESS, and sometimes decreasing the 
accuracy for large values of PESS. 
The poor performance of the prior knowledge method could stem from a few sources. It 
is possible that the MAF and GERP scores being used are simply not well-correlated with the 
predictiveness of common variants. The lack of correlation between the MAF and GERP scores 
suggests that either one or both of these scores is uncorrelated with the predictive variants. Either 
one is well-correlated with predictiveness and the other is not, or both are only somewhat 
correlated with predictiveness. If both the MAF and GERP scores were indeed correlated with 
predictiveness, there would be some level of correlation between them. 
It is also possible that an incorrect genetic model is being used. The prior pseudocount 
method assumes that the minor allele is the disease-causing allele, skewing the prior count table 
such that the disease prevalence is higher for the aa genotype, lower for the AA genotype, and 
unchanged for the Aa genotype. In effect, this assumes an additive model of disease association. 
If this model is not true for a SNP, the counts could skew in the wrong direction, potentially 
diluting genomic signal in the data rather than enhancing it. 
Finally, it is possible that the mapping from MAF or GERP score to the prior count table 
is being performed incorrectly. My experiments utilized an exponential mapping from MAF or 
GERP to the actual prior knowledge factor. While this does put more emphasis on the extreme 
MAF and GERP scores, it is possible that this weighting is not enough. An analysis by Gorlov et 
al. [4] suggests that it is indeed the rarest mutations which have the strongest associations with 
disease, but this may not hold true for SNPs with moderate to large MAF. It is possible that 
GERP and MAF are useful as priors only for rare to very rare SNVs. 
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6.1.3 Combination Method 
The combination score-based combination method was found to have relatively little impact 
when combining LP1 and the chi squared test. It is possible that the chi squared test is 
dominating this combination, because the chi squared test tends to result in smaller p-values than 
the LP1 metric. As the LP1’s α parameter increases, the resulting contingency table morphs from 
the original chi squared table with hard counts to a contingency table that represent diffusion 
using soft labels. These counts are by their nature less extreme, leading to less extreme 
distribution differences, and ultimately larger (less significant) p-values. The rank-based chi-
squared combination method had somewhat better results than the score-based method.  
The LP1+SLR rank-based method was generally worse than LP1 for small feature set 
sizes (where SLR performs worse), but better for larger feature set sizes (where SLR performs 
better). Applying ranks to the SLR-scored variables is somewhat different than the chi squared 
test, because most of the features under the SLR model get an identical score of 0. This means 
that all features not used in the SLR model get the maximum possible rank, while usually only 
about 500 features have true ranks. When averaging these ranks with LP1, this is almost 
performing an implicit feature selection step. Most variables’ combination ranks will be the LP1 
rank averaged with the maximum possible rank, putting them far down the ranking no matter 
what the LP1 rank is. Only features selected by SLR have a chance of being ranked highly. If 
SLR does select meaningful features, however, the ranking can be fine-tuned by the addition of 
the LP1 ranking. 
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6.2 FUTURE WORK 
The experimental work presented in this research explored the application of LP for biomarker 
discovery in genomic data. Several extensions and directions for future work are possible. 
While the prior knowledge method did not significantly improve the performance of LP1, 
there are a number of ways to modify it that might lead to improved performance. Fitting the 
proper genetic model to each SNP could improve the method, eliminating the case where the 
prior counts dilute the signal in the data rather than enhance it. It would be possible to utilize the 
LP3 scores directly to glean information about the genetic model of each SNP. In the LP3 model, 
each SNP allele is scored according to its association with the case or control group, so it is very 
simple to identify the risk and protective alleles simply by finding the allele with the largest 
positive and negative scores, respectively. This prior method is not totally independent of the 
data, but only utilizes the data to determine the direction of association and not the strength of 
the prior. 
Another way to determine the proper genetic model would be to examine each model 
exhaustively, and select the best-fitting model. A fully genotypic model could be analyzed by 
computing a statistic such as the chi squared criterion or the BIC for the 2x3 contingency table. 
Other models would be represented by a collapsed, 2x2 version of the contingency table. The 
recessive model, for instance, would be a result of combining the AA and Aa columns, while the 
dominant model would combine the Aa and aa columns. 
Yet another method of including prior knowledge could be to include pseudocount bias 
nodes in the network propagation. In this method the graph would be initialized with two extra 
sample nodes having labels +1 and -1 which are connected to every feature node in the graph. 
These nodes’ labels are fixed, and do not update at any step of the iterative propagation process. 
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The prior knowledge is encapsulated as edge weights which connects the bias nodes to the 
feature nodes. For a SNP with no prior belief of association, the weights connecting to the bias 
nodes are 0, meaning they have no effect on the propagation equations for that SNP. On the other 
hand, SNPs with prior evidence of association are have increased weights connecting to the bias 
nodes, indicating a larger pseudocount of cases or controls for a particular SNP allele. This 
allows the prior knowledge to actually have an effect on the propagation itself, rather than just 
being added as pseudocounts at the end (as is described in 3.4.2.2).  
The ranking combination method proved to be effective for the LP1+SLR rank-based 
method using a moderate number of features. This could possibly be a result of the implicit 
feature selection step that SLR undertakes. Instead of directly averaging ranks, it might also be 
effective to perform a two-step ranking by using an implicitly selective algorithm like SLR 
followed by ranking only those selected variants. This could potentially overcome SLR’s 
problem of low predictive performance for small feature set sizes. 
Finally, the LP algorithm is a semi-supervised algorithm, but I did not fully explore how 
the algorithm might utilize unlabeled data. Unlabeled sample nodes would represent individuals 
for whom we have the genotype, but no phenotype. Additional unlabeled samples could add 
extra diffusion paths to the graph, reinforcing functional modules and affecting the network 
propagation. This might ultimately allow the LP algorithm to leverage disparate data sources 
where the phenotype is unlabeled or uncertain, potentially improving the algorithm’s ability to 
select meaningful variants. 
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APPENDIX A 
AUC RESULTS FOR GWAS DATASTES 
This Appendix contains the AUC results obtained from all classification experiments. Each table 
(Table 26 though Table 34) gives results for one GWAS dataset and gives the dataset name, the 
feature ranking algorithms that were used, and the number of features used in the kNN classifier. 
ChiSq refers to the chi squared test, SLR is the sparse logistic regression method, LP3 is the 
original LP algorithm with α = 0.25, and LP1 is the single-score extension with α = 0.25. 
LP1+GERP50 refers to the LP1 score using the GERP prior with PESS set to 50, while 
LP1+GERP500 refers to the GERP prior with PESS set to 500. The experiments using the MAF 
prior are named in an analogous fashion. The last set of experiments is the combination methods, 
which combine LP1 with chi squared or SLR, using both rank and score-based methods. 
Table 26 - Classification AUC results for TGen data. 
TGen 1 2 5 10 50 100 500 1000 
ChiSq 0.6992 0.6945 0.7220 0.7394 0.7060 0.6574 0.6013 0.5953 
95% CI ±0.0139 0.0141 ±0.0136 ±0.0132 ±0.0140 ±0.0148 ±0.0155 ±0.0154 
SLR 0.6783 0.6876 0.7291 0.7424 0.7264 - - - 
95% CI ±0.0144 ±0.0137 ±0.0134 ±0.0131 ±0.0131 - - - 
LP3 0.6733 0.6904 0.7088 0.7369 0.7519 0.7286 0.6138 0.5735 
95% CI ±0.0144 ±0.0137 ±0.0139 ±0.0131 ±0.0135 ±0.0137 ±0.0131 ±0.0154 
LP1 0.6992 0.6945 0.7230 0.7118 0.6694 0.6473 0.5958 0.5820 
95% CI ±0.0139 ±0.0141 ±0.0136 ±0.0138 ±0.0145 ±0.0149 ±0.0154 ±0.0156 
LP1+GERP50 0.6992 0.6945 0.7228 0.7145 0.6587 0.6426 0.5725 0.5620 
95% CI ±0.0139 ±0.0141 ±0.0136 ±0.0138 ±0.0145 ±0.0149 ±0.0154 ±0.0156 
LP1+GERP500 0.5165 0.5076 0.5112 0.5108 0.5145 0.5088 0.4923 0.4986 
95% CI ±0.0164 ±0.0164 ±0.0166 ±0.0166 ±0.0166 ±0.0166 ±0.0166 ±0.0166 
LP1+MAF50 0.6992 0.6945 0.7014 0.6983 0.6455 0.6326 0.5488 0.5313 
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95% CI ±0.0139 ±0.0141 ±0.0136 ±0.0138 ±0.0145 ±0.0149 ±0.0154 ±0.0156 
LP1+MAF500 0.5025 0.5110 0.5102 0.5129 0.5123 0.5101 0.4988 0.4976 
95% CI ±0.0164 ±0.0164 ±0.0166 ±0.0166 ±0.0166 ±0.0166 ±0.0166 ±0.0166 
LP1+ChiSq_Score 0.6992 0.6945 0.7230 0.7234 0.6905 0.6458 0.5852 0.5871 
95% CI ±0.0139 ±0.0141 ±0.0136 ±0.0138 ±0.0139 ±0.0149 ±0.0154 ±0.0156 
LP1+ChiSq_Rank 0.6992 0.6945 0.7230 0.6873 0.6635 0.6217 0.5746 0.5321 
95% CI ±0.0139 ±0.0141 ±0.0136 ±0.0140 ±0.0145 ±0.0149 ±0.0154 ±0.0156 
LP1+SLR_Rank 0.6992 0.6945 0.7214 0.7336 0.7251 0.6378 0.5755 0.5713 
95% CI ±0.0139 ±0.0141 ±0.0134 ±0.0131 ±0.0132 ±0.0149 ±0.0154 ±0.0156 
 
 
Table 27 - Classification AUC results for ADRC data. 
ADRC 1 2 5 10 50 100 500 1000 
ChiSq 0.6834 0.7369 0.7433 0.7184 0.6438 0.6034 0.5445 0.5349 
95% CI ±0.0112 ±0.0105 ±0.0104 ±0.0108 ±0.0116 ±0.0120 ±0.0122 ±0.0122 
SLR 0.6834 0.6911 0.7100 0.7354 0.6970 0.6874 - - 
95% CI ±0.0112 ±0.0111 ±0.0109 ±0.0105 ±0.0111 ±0.0112 - - 
LP3 0.6325 0.6756 0.7342 0.7315 0.7151 0.7154 0.6096 0.5435 
95% CI ±0.0117 ±0.0105 ±0.0110 ±0.0110 ±0.0107 ±0.0109 ±0.0104 ±0.0122 
LP1 0.6834 0.7369 0.7433 0.7058 0.6264 0.5862 0.5383 0.5228 
95% CI ±0.0112 ±0.0105 ±0.0104 ±0.0110 ±0.0118 ±0.0121 ±0.0123 ±0.0123 
LP1+GERP50 0.6834 0.7369 0.7433 0.7102 0.6133 0.5789 0.5464 0.5173 
95% CI ±0.0112 ±0.0105 ±0.0104 ±0.0110 ±0.0118 ±0.0121 ±0.0123 ±0.0123 
LP1+GERP500 0.4975 0.5033 0.5043 0.5138 0.5057 0.5102 0.5013 0.5082 
95% CI ±0.0164 ±0.0164 ±0.0166 ±0.0166 ±0.0166 ±0.0166 ±0.0166 ±0.0166 
LP1+MAF50 0.6834 0.7369 0.7345 0.7001 0.6023 0.5643 0.5523 0.5069 
95% CI ±0.0112 ±0.0105 ±0.0104 ±0.0110 ±0.0118 ±0.0121 ±0.0123 ±0.0123 
LP1+MAF500 0.5025 0.5054 0.5068 0.5264 0.5148 0.5089 0.5166 0.5009 
95% CI ±0.0164 ±0.0164 ±0.0166 ±0.0166 ±0.0166 ±0.0166 ±0.0166 ±0.0166 
LP1+ChiSq_Score 0.6834 0.7369 0.7433 0.7111 0.6361 0.5915 0.5441 0.5101 
95% CI ±0.0112 ±0.0105 ±0.0104 ±0.0109 ±0.0117 ±0.0121 ±0.0123 ±0.0129 
LP1+ChiSq_Rank 0.6834 0.7369 0.7233 0.7027 0.6254 0.5619 0.5303 0.5216 
95% CI ±0.0112 ±0.0105 ±0.0104 ±0.0111 ±0.0119 ±0.0122 ±0.0125 ±0.0126 
LP1+SLR_Rank 0.6834 0.7369 0.7433 0.7244 0.6518 0.6152 0.5401 0.5233 
95% CI ±0.0112 ±0.0105 ±0.0104 ±0.0110 ±0.0116 ±0.0119 ±0.0122 ±0.0123 
 
 
Table 28 - Classification AUC results for BD WTCCC data. 
BD 1 2 5 10 50 100 500 1000 
ChiSq 0.5358 0.5724 0.6056 0.5846 0.5372 0.5300 0.5301 0.5220 
95% CI ±0.0164 ±0.0166 ±0.0164 ±0.0166 ±0.0166 ±0.0168 ±0.0166 ±0.0166 
SLR 0.5353 0.5461 0.5975 0.6166 0.5874 0.5742 - - 
95% CI ±0.0166 ±0.0164 ±0.0164 ±0.0164 ±0.0165 ±0.0165 - - 
LP3 0.5211 0.5478 0.5478 0.5532 0.5219 0.5190 0.5089 0.4911 
95% CI ±0.0167 ±0.0169 ±0.0169 ±0.0169 ±0.0169 ±0.0169 ±0.0167 ±0.0167 
LP1 0.5366 0.5653 0.6270 0.6137 0.5348 0.5328 0.5318 0.5365 
95% CI ±0.0165 ±0.0163 ±0.0161 ±0.0163 ±0.0167 ±0.0167 ±0.0167 ±0.0167 
LP1+GERP50 0.5349 0.5653 0.6270 0.6131 0.5376 0.5278 0.5331 0.5379 
95% CI ±0.0165 ±0.0163 ±0.0161 ±0.0163 ±0.0167 ±0.0167 ±0.0167 ±0.0167 
LP1+GERP500 0.5075 0.5067 0.5108 0.5118 0.5037 0.5095 0.4933 0.5042 
95% CI ±0.0165 ±0.0165 ±0.0167 ±0.0167 ±0.0167 ±0.0167 ±0.0167 ±0.0167 
LP1+MAF50 0.5349 0.5653 0.6160 0.6034 0.5485 0.5153 0.5355 0.5324 
95% CI ±0.0165 ±0.0163 ±0.0161 ±0.0163 ±0.0167 ±0.0167 ±0.0167 ±0.0167 
LP1+MAF500 0.5066 0.5061 0.5111 0.5118 0.5024 0.5084 0.4926 0.4958 
95% CI ±0.0165 ±0.0165 ±0.0167 ±0.0167 ±0.0167 ±0.0167 ±0.0167 ±0.0167 
LP1+ChiSq_Score 0.5366 0.5701 0.6150 0.6011 0.5392 0.5324 0.5366 0.5214 
 95 
95% CI ±0.0165 ±0.0163 ±0.0162 ±0.0164 ±0.0167 ±0.0167 ±0.0167 ±0.0168 
LP1+ChiSq_Rank 0.5262 0.5514 0.6053 0.6022 0.5217 0.5246 0.5291 0.5107 
95% CI ±0.0166 ±0.0164 ±0.0164 ±0.0164 ±0.0168 ±0.0168 ±0.0168 ±0.0169 
LP1+SLR_Rank 0.5302 0.5514 0.6053 0.6022 0.5656 0.5612 0.5291 0.5107 
95% CI ±0.0166 ±0.0164 ±0.0164 ±0.0164 ±0.0168 ±0.0168 ±0.0168 ±0.0169 
 
 
 
Table 29 - Classification AUC results for CAD WTCCC data. 
CAD 1 2 5 10 50 100 500 1000 
ChiSq 0.5991 0.6804 0.7702 0.8201 0.5643 0.5368 0.5295 0.5224 
95% CI ±0.0159 ±0.0149 ±0.0129 ±0.0116 ±0.0165 ±0.0167 ±0.0165 ±0.0165 
SLR 0.4949 0.5408 0.6291 0.7840 0.6568 0.5993 - - 
95% CI ±0.0163 ±0.0163 ±0.0157 ±0.0127 ±0.0149 ±0.0157 - - 
LP3 0.5503 0.5999 0.6612 0.7109 0.5860 0.5420 0.5218 0.5120 
95% CI ±0.0171 ±0.0167 ±0.0163 ±0.0159 ±0.0165 ±0.0167 ±0.0167 ±0.0167 
LP1 ±0.6804 0.6804 0.7668 0.8372 0.6254 0.5452 0.5224 0.5239 
95% CI ±0.0149 ±0.0149 ±0.0129 ±0.0108 ±0.0161 ±0.0165 ±0.0167 ±0.0165 
LP1+GERP50 0.6804 0.6804 0.7668 0.8372 0.5950 0.5514 0.5102 0.5114 
95% CI ±0.0149 ±0.0149 ±0.0129 ±0.0108 ±0.0163 ±0.0165 ±0.0165 ±0.0165 
LP1+GERP500 0.6021 0.6804 0.7489 0.8063 0.5903 0.5307 0.5152 0.5036 
95% CI ±0.0157 ±0.0149 ±0.0135 ±0.0120 ±0.0163 ±0.0165 ±0.0165 ±0.0165 
LP1+MAF50 0.6804 0.6804 0.7502 0.8361 0.6055 0.5489 0.5202 0.5164 
95% CI ±0.0149 ±0.0149 ±0.0129 ±0.0108 ±0.0163 ±0.0165 ±0.0165 ±0.0165 
LP1+MAF500 0.5568 0.6523 0.7023 0.7356 0.5842 0.5267 0.5173 0.4943 
95% CI ±0.0157 ±0.0149 ±0.0135 ±0.0120 ±0.0163 ±0.0165 ±0.0165 ±0.0165 
LP1+ChiSq_Score ±0.6719 0.6804 0.7668 0.8118 0.5718 0.5515 0.5316 0.5249 
95% CI ±0.0149 ±0.0149 ±0.0129 ±0.0120 ±0.0165 ±0.0165 ±0.0167 ±0.0165 
LP1+ChiSq_Rank ±0.6619 0.6744 0.7501 0.8007 0.5525 0.5489 0.5304 0.5275 
95% CI ±0.0149 ±0.0149 ±0.0129 ±0.0120 ±0.0165 ±0.0165 ±0.0167 ±0.0165 
LP1+SLR_Rank ±0.6628 0.6689 0.7504 0.8016 0.6548 0.5540 0.5314 0.5228 
95% CI ±0.0149 ±0.0149 ±0.0129 ±0.0120 ±0.0149 ±0.0165 ±0.0167 ±0.0165 
 
 
Table 30 - Classification AUC results for CD WTCCC data. 
CD 1 2 5 10 50 100 500 1000 
ChiSq 0.5509 0.5766 0.6225 0.6346 0.5796 0.5950 0.5656 0.5605 
95% CI ±0.0171 ±0.0169 ±0.0165 ±0.0163 ±0.0171 ±0.0167 ±0.0171 ±0.0169 
SLR 0.5509 0.5486 0.5859 0.6285 0.6027 0.6188 - - 
95% CI ±0.0171 ±0.0172 ±0.0167 ±0.0163 ±0.0165 ±0.0163 - - 
LP3 0.5506 0.5540 0.5414 0.5548 0.5314 0.5146 0.5073 0.5039 
95% CI ±0.0171 ±0.0171 ±0.0172 ±0.0172 ±0.0171 ±0.0172 ±0.0171 ±0.0171 
LP1 0.5509 0.5766 0.6288 0.6371 0.5791 0.5872 0.5664 0.5365 
95% CI ±0.0171 ±0.0169 ±0.0165 ±0.0163 ±0.0169 ±0.0167 ±0.0169 ±0.0171 
LP1+GERP50 0.5509 0.5822 0.6236 0.6358 0.5870 0.5805 0.5750 0.5488 
95% CI ±0.0171 ±0.0169 ±0.0165 ±0.0163 ±0.0169 ±0.0169 ±0.0169 ±0.0171 
LP1+GERP500 0.4986 0.4977 0.5085 0.5465 0.5046 0.5073 0.5530 0.5550 
95% CI ±0.0167 ±0.0167 ±0.0171 ±0.0172 ±0.0171 ±0.0171 ±0.0171 ±0.0169 
LP1+MAF50 0.5509 0.5822 0.6212 0.6316 0.5901 0.5640 0.5547 0.5364 
95% CI ±0.0171 ±0.0169 ±0.0165 ±0.0163 ±0.0169 ±0.0169 ±0.0169 ±0.0171 
LP1+MAF500 0.4986 0.4977 0.5065 0.5115 0.5048 0.5013 0.5530 0.5317 
95% CI ±0.0167 ±0.0167 ±0.0171 ±0.0172 ±0.0171 ±0.0171 ±0.0171 ±0.0169 
LP1+ChiSq_Score 0.5509 0.5766 0.6259 0.6349 0.5618 0.5873 0.5648 0.5422 
95% CI ±0.0171 ±0.0169 ±0.0165 ±0.0163 ±0.0169 ±0.0167 ±0.0169 ±0.0171 
LP1+ChiSq_Rank 0.5509 0.5766 0.6284 0.6224 0.5652 0.5676 0.5548 0.5434 
95% CI ±0.0171 ±0.0169 ±0.0165 ±0.0163 ±0.0169 ±0.0169 ±0.0169 ±0.0171 
 96 
LP1+SLR_Rank 0.5509 0.5512 0.6118 0.6371 0.6012 0.6033 0.5562 0.5431 
95% CI ±0.0171 ±0.0171 ±0.0165 ±0.0163 ±0.0165 ±0.0165 ±0.0169 ±0.0171 
 
 
Table 31 - Classification AUC results for HT WTCCC data. 
HT 1 2 5 10 50 100 500 1000 
ChiSq 0.5344 0.5359 0.5519 0.5530 0.5263 0.5362 0.5355 0.5400 
95% CI ±0.0165 ±0.0165 ±0.0167 ±0.0165 ±0.0167 ±0.0165 ±0.0165 ±0.0163 
SLR 0.5354 0.5463 0.5756 0.5885 0.5774 0.5671 - - 
95% CI ±0.0165 ±0.0167 ±0.0165 ±0.0163 ±0.0163 ±0.0165 - - 
LP3 0.5003 0.5066 0.4959 0.4904 0.5060 0.4921 0.4934 0.5021 
95% CI ±0.0163 ±0.0163 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.0167 
LP1 0.5322 0.5481 0.5601 0.5711 0.5684 0.5391 0.5280 0.5378 
95% CI ±0.0165 ±0.0165 ±0.0167 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.0165 
LP1+GERP50 0.5322 0.5518 0.5625 0.5715 0.5430 0.5364 0.5368 0.5354 
95% CI ±0.0165 ±0.0165 ±0.0167 ±0.0165 ±0.0167 ±0.0167 ±0.0167 ±0.0167 
LP1+GERP500 0.5036 0.5092 0.4946 0.4742 0.4987 0.4905 0.5019 0.5118 
95% CI ±0.0163 ±0.0163 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.0167 
LP1+MAF50 0.5322 0.5518 0.5522 0.5604 0.5497 0.5456 0.5325 0.5276 
95% CI ±0.0165 ±0.0165 ±0.0167 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.067 
LP1+MAF500 0.5036 0.5092 0.5002 0.4841 0.4964 0.4921 0.5009 0.5017 
95% CI ±0.0163 ±0.0163 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.0167 
LP1+ChiSq_Score 0.5301 0.5368 0.5546 0.5670 0.5407 0.5391 0.5280 0.5378 
95% CI ±0.0165 ±0.0165 ±0.0167 ±0.0165 ±0.0167 ±0.0167 ±0.0167 ±0.0167 
LP1+ChiSq_Rank 0.5322 0.5481 0.5501 0.5529 0.5548 0.5307 0.5344 0.5299 
95% CI ±0.0165 ±0.0165 ±0.0167 ±0.0165 ±0.0165 ±0.0165 ±0.0165 ±0.0165 
LP1+SLR_Rank 0.5352 0.5462 0.5661 0.5802 0.5715 0.5642 0.5318 0.5312 
95% CI ±0.0165 ±0.0165 ±0.0164 ±0.0163 ±0.0163 ±0.0165 ±0.0165 ±0.0165 
 
 
Table 32 - Classification AUC results for RA WTCCC data. 
RA 1 2 5 10 50 100 500 1000 
ChiSq 0.5891 0.6313 0.7013 0.7273 0.6107 0.5884 0.5467 0.5434 
95% CI ±0.0169 ±0.0165 ±0.0153 ±0.0149 ±0.0163 ±0.0165 ±0.0167 ±0.0167 
SLR 0.5891 0.6159 0.6902 0.7382 0.7055 0.6711 - - 
95% CI ±0.0169 ±0.0169 ±0.0155 ±0.0145 ±0.0151 ±0.0157 - - 
LP3 0.5849 0.6109 0.6260 0.6352 0.5852 0.5719 0.5247 0.5133 
95% CI ±0.0169 ±0.0169 ±0.0169 ±0.0167 ±0.0169 ±0.0169 ±0.0169 ±0.0167 
LP1 0.5891 0.6313 0.7013 0.7284 0.6398 0.5946 0.5565 0.5531 
95% CI ±0.0169 ±0.0165 ±0.0153 ±0.0149 ±0.0163 ±0.0165 ±0.0167 ±0.0167 
LP1+GERP50 0.5891 0.6313 0.7028 0.7282 0.6377 0.6009 0.5547 0.5410 
95% CI ±0.0169 ±0.0165 ±0.0153 ±0.0149 ±0.0163 ±0.0165 ±0.0165 ±0.0165 
LP1+GERP500 0.5891 0.5950 0.6005 0.6654 0.5914 0.5698 0.5496 0.5588 
95% CI ±0.0169 ±0.0167 ±0.0169 ±0.0159 ±0.0167 ±0.0167 ±0.0165 ±0.0167 
LP1+MAF50 0.5891 0.6313 0.6969 0.7118 0.6291 0.6015 0.5436 0.5398 
95% CI ±0.0169 ±0.0165 ±0.0153 ±0.0149 ±0.0163 ±0.0165 ±0.0165 ±0.0165 
LP1+MAF500 0.5502 0.5680 0.5985 0.6254 0.5724 0.5448 0.5305 0.5418 
95% CI ±0.0169 ±0.0167 ±0.0169 ±0.0159 ±0.0167 ±0.0167 ±0.0165 ±0.0167 
LP1+ChiSq_Score 0.5891 0.6313 0.7013 0.7280 0.6218 0.5881 0.5538 0.5502 
95% CI ±0.0169 ±0.0165 ±0.0153 ±0.0149 ±0.0163 ±0.0165 ±0.0167 ±0.0167 
LP1+ChiSq_Rank 0.5891 0.6313 0.7013 0.7225 0.6010 0.5891 0.5322 0.5294 
95% CI ±0.0169 ±0.0165 ±0.0153 ±0.0149 ±0.0163 ±0.0165 ±0.0167 ±0.0167 
LP1+SLR_Rank 0.5891 0.6313 0.7007 0.7318 0.6623 0.6583 0.5646 0.5514 
95% CI ±0.0169 ±0.0165 ±0.0153 ±0.0149 ±0.0153 ±0.0152 ±0.0167 ±0.0167 
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Table 33 - Classification AUC results for T1D WTCCC data. 
T1D 1 2 5 10 50 100 500 1000 
ChiSq 0.6777 0.7047 0.7448 0.7293 0.6562 0.5905 0.5733 0.5480 
95% CI ±0.0149 ±0.0143 ±0.0135 ±0.0139 ±0.0153 ±0.0161 ±0.0163 ±0.0163 
SLR 0.5007 0.5490 0.7346 0.7202 0.6841 0.6639 - - 
95% CI ±0.0163 ±0.0165 ±0.0137 ±0.0131 ±0.0139 ±0.0147 - - 
LP3 0.6093 0.6617 0.6891 0.6900 0.6678 0.6301 0.5461 0.5384 
95% CI ±0.0157 ±0.0155 ±0.0151 ±0.0151 ±0.0153 ±0.0159 ±0.0165 ±0.0165 
LP1 0.6863 0.7047 0.7448 0.7329 0.6704 0.6054 0.5614 0.5602 
95% CI ±0.0147 ±0.0143 ±0.0135 ±0.0137 ±0.0151 ±0.0159 ±0.0163 ±0.0163 
LP1+GERP50 0.6863 0.7047 0.7445 0.7306 0.6624 0.5983 0.5609 0.5585 
95% CI ±0.0147 ±0.0143 ±0.0135 ±0.0139 ±0.0153 ±0.0161 ±0.0163 ±0.0163 
LP1+GERP500 0.6777 0.7047 0.7093 0.7040 0.6383 0.6077 0.5553 0.5499 
95% CI ±0.0149 ±0.0143 ±0.0141 ±0.0143 ±0.0155 ±0.0161 ±0.0165 ±0.0165 
LP1+MAF50 0.6863 0.7047 0.7445 0.7296 0.6544 0.5838 0.5567 0.5445 
95% CI ±0.0147 ±0.0143 ±0.0135 ±0.0139 ±0.0153 ±0.0161 ±0.0163 ±0.0163 
LP1+MAF500 0.6213 0.6534 0.6875 0.6755 0.6212 0.6014 0.5448 0.5237 
95% CI ±0.0147 ±0.0139 ±0.0139 ±0.0141 ±0.0153 ±0.0161 ±0.0165 ±0.0165 
LP1+ChiSq_Score 0.6779 0.7047 0.7448 0.7301 0.6700 0.6045 0.5718 0.5542 
95% CI ±0.0149 ±0.0143 ±0.0135 ±0.0137 ±0.0151 ±0.0159 ±0.0163 ±0.0163 
LP1+ChiSq_Rank 0.6863 0.7047 0.7448 0.7316 0.6702 0.5984 0.5673 0.5519 
95% CI ±0.0147 ±0.0143 ±0.0135 ±0.0137 ±0.0151 ±0.0159 ±0.0163 ±0.0163 
LP1+SLR_Rank 0.6434 0.6627 0.7418 0.7311 0.6819 0.6547 0.6012 0.5631 
95% CI ±0.0147 ±0.0143 ±0.0135 ±0.0137 ±0.0151 ±0.0147 ±0.0161 ±0.0163 
 
 
Table 34 - Classification AUC results for T2D WTCCC data. 
T2D 1 2 5 10 50 100 500 1000 
ChiSq 0.5599 0.6498 0.7780 0.7329 0.5707 0.5611 0.5358 0.5201 
95% CI ±0.0167 ±0.0157 ±0.0129 ±0.0141 ±0.0165 ±0.0163 ±0.0167 0.0167 
SLR 0.4916 0.6015 0.6751 0.7424 0.7258 0.6671 - - 
95% CI ±0.0165 ±0.0159 ±0.0151 ±0.0139 ±0.0143 ±0.0155 - - 
LP3 0.5521 0.6091 0.6903 0.6907 0.6071 0.5773 0.5293 0.5232 
95% CI ±0.0167 ±0.0167 ±0.0161 ±0.0161 ±0.0165 ±0.0165 ±0.0165 0.0165 
LP1 0.6862 0.6862 0.7787 0.7622 0.5804 0.5614 0.5432 0.5506 
95% CI ±0.0149 ±0.0149 ±0.0129 ±0.0135 ±0.0165 ±0.0165 ±0.0167 ±0.0165 
LP1+GERP50 0.6862 0.6862 0.7739 0.7551 0.5703 0.5640 0.5492 0.5544 
95% CI ±0.0149 ±0.0149 ±0.0131 ±0.0135 ±0.0165 ±0.0165 ±0.0165 ±0.0165 
LP1+GERP500 0.6009 0.6862 0.7320 0.7573 0.5715 0.5455 0.5160 0.5162 
95% CI ±0.0159 ±0.0149 ±0.0139 ±0.0135 ±0.0165 ±0.0165 ±0.0167 ±0.0165 
LP1+MAF50 0.6862 0.6862 0.7669 0.7485 0.5693 0.5542 0.5313 0.5315 
95% CI ±0.0149 ±0.0149 ±0.0131 ±0.0135 ±0.0165 ±0.0167 ±0.0167 ±0.0167 
LP1+MAF500 0.5595 0.5786 0.6255 0.6548 0.5685 0.5326 0.5061 0.5081 
95% CI ±0.0163 ±0.0157 ±0.0153 ±0.0141 ±0.0165 0±.0167 ±0.0167 ±0.0165 
LP1+ChiSq_Score 0.6862 0.6582 0.7783 0.7514 0.5794 0.5610 0.5412 0.5386 
95% CI ±0.0149 ±0.0153 ±0.0129 ±0.0135 ±0.0165 ±0.0165 ±0.0167 ±0.0165 
LP1+ChiSq_Rank 0.5832 0.6245 0.7546 0.7465 0.5771 0.5596 0.5483 0.5372 
95% CI ±0.0164 ±0.0159 ±0.0129 ±0.0139 ±0.0165 ±0.0165 ±0.0167 ±0.0165 
LP1+SLR_Rank 0.6641 0.6714 0.7603 0.7575 0.6853 0.6608 0.6035 0.5616 
95% CI ±0.0152 ±0.0151 ±0.0129 ±0.0136 ±0.0150 ±0.0165 ±0.0163 ±0.0165 
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APPENDIX B 
BIOLOGICAL VALIDITY RESULTS FOR GWAS DATASETS 
This Appendix contains the results of the biological validation experiment for each of the control 
algorithms (ChiSq, SWRF, SLR, and LP3) on the two LOAD datasets (TGen and ADRC). Each 
table (see Tables 35 to 42) gives the top 25 SNPs as ranked by each control algorithm, with the 
associated chromosome, gene, and literature reference. The LP1 biological validation results may 
be found in Section 5.1.3.2. SNPs with literature validation results are highlighted in grey. 
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Table 35 - Top 25 SNPs as ranked by LP3 (α = 0.25) for TGen data. 
Rank rsID Gene Chr Comment 
1 rs7412 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
2 rs4420638 APOC 19 In strong linkage disequilibrium with APOE SNPs [156] 
3 rs429358 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
4 rs10824310 PRKG1 10 Significant association with LOAD [55] 
5 rs12162084 - 16 Significant association with LOAD [157] 
6 rs17330779 NRCAM 7 Associated with axonal degeneration in LOAD [158] 
7 rs7077757 RBM20 10 Meta-analysis of multiple studies showed association [159] 
8 rs10115381 - 9 - 
9 rs4356530 - 17 Association found in another analysis of TGen data [59] 
10 rs6717497 - 2 - 
11 rs2913719 - 5 Association in systematic meta-analysis of AD [69] 
12 rs12476792 - 2 - 
13 rs17169622 BMPER 7 - 
14 rs1038891 LRRC4C 11 SNP associated with LOAD in genome-wide analysis [61] 
15 rs10499687 VWC2 7 - 
16 rs7335085 - 13 - 
17 rs16974268 SLCO3A1 15 - 
18 rs10996618 - 10 SNP selected in logistic regression analysis [62] 
19 rs950922 ALPL 1 - 
20 rs17151710 - 5 Found in meta-analysis of 3 studies [160] 
21 rs9934599 IL34 16 - 
22 rs473367 - 9 SNP may interact with APOE to affect LOAD [161] 
23 rs4862146 - 4 Glycoprotein buildup affects nerve cells in the brain [162] 
24 rs6013406 ZFP64 20 - 
25 rs1712417 TMEM87A 15 - 
 
Table 36 - Top 25 SNPs as ranked by LP3 (α = 0.25) for ADRC data. 
Rank rsID Gene Chr Comment 
1 rs439401 APOE 19 In strong LD with rs7412 and rs429358 [63] 
2 rs5157 APOC4 19 In strong LD with other APOC risk SNPs [64] 
3 rs2075650 TOMM40 19 Predictive of longevity of LOAD patients [163, 164] 
4 rs445925 - 19 Showed LOAD association in African-American cohort [65] 
5 rs157182 ZNF433 19 Other zinc finger proteins linked to LOAD [165] 
6 rs283129 PIN1 5 PIN1 linked to neural apoptosis in LOAD [166, 167] 
7 rs17428956 - 1 - 
8 rs11076978 - 16 - 
9 rs5749272 NDRG1 22 NDRG family linked to neuron development, LOAD [168, 169] 
10 rs6754487 - 2 - 
11 rs439401 - 19 Near APOE, associated with LOAD [170] 
12 rs3738269 IGFN1 1 - 
13 rs10106829 LOC157273 8 - 
14 rs12520115 - 5 - 
15 rs17018886 - 2 - 
16 rs17821171 - 15 - 
17 rs523079 - 3 - 
18 rs2314221 - 2 - 
19 rs13059988 - 3 - 
20 rs356611 - 5 - 
21 rs10976056 KDM4C 9 - 
22 rs10489926 PRG5 1 Brain-specific protein linked to axonal health [171] 
23 rs10489924 PRG5 1 Brain-specific protein linked to axonal health [171] 
24 rs2712599 - 12 - 
25 rs10459209 - 12 - 
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Table 37 - Top 25 SNPs as ranked by SLR for TGen data. 
Rank rsID Gene Chr Comment 
1 rs7412 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
2 rs429358 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
3 rs7662187 PDGFC 4 - 
4 rs10778921 TMTC2 12 - 
5 rs7335085 - 13 - 
6 rs12162084 - 16 Association found in another analysis of TGen data [157]  
7 rs16923249 - 9 - 
8 rs6508182 DCC 18 Implicated in axonal development [172] 
9 rs4902299 - 14 - 
10 rs10510990 - 3 - 
11 rs16916338 GABBR2 9 Gene involved in neurotransmitters [10] 
12 rs10894424 NTM 11 Gene implicated in LOAD [173] 
13 rs1728390 - 16 - 
14 rs4351927 GPC5 13 Involved in neuronal development [174] 
15 rs16907781 ZBTB10 8 - 
16 rs10871528 - 18 - 
17 rs7848622 - 9 - 
18 rs11846241 EML5 14 - 
19 rs17044664 - 3 - 
20 rs6540253 - 16 - 
21 rs10176594 - 2 - 
22 rs7243005 - 18 - 
23 rs10740667 - 10 - 
24 rs10966006 - 9 - 
25 rs6824979 MMRN1 4 - 
 
Table 38 - Top 25 SNPs as ranked by SLR for ADRC data. 
Rank rsID Gene Chr Comment 
1 rs429358 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
2 rs4420638 APOC 19 In strong linkage disequilibrium with APOE SNPs [156] 
3 rs7412 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [53] 
4 rs8083752 LOC643542 18 - 
5 rs1978326 MAGI2 7 Gene associated with hippocampal volume reduction in AD [170] 
6 rs6015314 APCDD1L-AS1 20 - 
7 rs17767748 BTRC 10 - 
8 rs11695991 NEU2 2 - 
9 rs7210298 - 17 - 
10 rs12190755 ZNF318 6 Gene expression level linked to AD [175] 
11 rs7606208 SLC9A2 2 - 
12 rs9932776 - 16 - 
13 rs11680648 DIRC3 2 - 
14 rs12100042 - 13 - 
15 rs12257119 MYO3A 10 - 
16 rs4147209 - 1 - 
17 rs17099379 SYT16 14 - 
18 rs7009155 - - - 
19 rs801289 - 2 - 
20 rs10862184 MYF5 12 - 
21 rs16846388 SPATA16 3 - 
22 rs9299784 KIAA1217 10 - 
23 rs1759320 - 10 - 
24 rs10507341 - 13 - 
25 rs2276754 CCDC174 3 - 
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Table 39 - Top 25 SNPs as ranked by SWRF for TGen data. 
Rank rsID Gene Chr Comment 
1 rs7412 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
2 rs250857 FSTL4 5 - 
3 rs9328529 - 9 - 
4 rs934745 MAPK4 18 - 
5 rs11077058 RBFOX1 16 RBFOX1 linked to brain volume in older adults [176] 
6 s17124810 CBFA2T2 20 - 
7 rs1251059 - 12 - 
8 rs9908065 - 17 - 
9 rs13213247 - 6 Significant association in meta-analysis of LOAD [177] 
10 rs8112622 - 19 - 
11 rs2779556 GABBR2 9 Gene involved in neurological pathways [178] 
12 rs188429 RCL1 9 - 
13 rs8108780 - 19 - 
14 rs2796460 TLE1 9 - 
15 rs16910463 - 9 - 
16 rs16915130 GRM5 11 Gene is a coreceptor for LOAD-related protein [179] 
17 rs16967491 - 15 - 
18 rs200556 - 9 - 
19 rs250855 FSTL4 5 - 
20 rs4394475 - 9 - 
21 rs10454604 - 13 - 
22 rs8006542 FOXN3 14 - 
23 rs865505 - 12 - 
24 rs2712271 - 1 - 
25 rs17141368 - 7 - 
 
Table 40 - Top 25 SNPs as ranked by SWRF for ADRC data. 
Rank rsID Gene Chr Comment 
1 rs439401 - 19 Significant LOAD association [63] 
2 rs445925 - 19 Located between APOE and APOC genes [68] 
3 rs6434513 - 2 - 
4 rs17245472 - 16 - 
5 rs182662 RAB23 6 - 
6 rs4494677 - 2 - 
7 rs16906827 - 10 - 
8 rs11108379 LTA4H 12 - 
9 rs12683673 KDM4C 9 - 
10 rs2712599 - 12 - 
11 rs9297095 - 6 - 
12 rs4270681 - 5 - 
13 rs12592188 - 15 - 
14 rs2442968 - 18 - 
15 rs2442966 - 18 - 
16 rs1834804 - 14 - 
17 rs16963657 - 13 - 
18 rs11820815 - 11 - 
19 rs1892786 - 11 - 
20 rs7004779 KCNK9 8 - 
21 rs6669982 NFIA 1 - 
22 rs9493552 - 6 - 
23 rs11004700 - 10 - 
24 rs6678065 NFIA 1 - 
25 rs10095543 - 8 - 
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Table 41 - Top 25 SNPs as ranked by chi squared for TGen data. 
Rank rsID Gene Chr Comment 
1 rs4420638 APOC 19 In strong linkage disequilibrium with APOE SNPs [156] 
2 rs7412 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
3 rs934745 MAPK4 18 - 
4 rs429358 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
5 rs7079348 C10orf11 10 - 
6 rs188429 RCL1 9 - 
7 rs10824310 PRKG1 10 Significant association with LOAD [55] 
8 rs6717497 - 2 - 
9 rs16938663 STAU2 8 - 
10 rs3732443 GXYLT2 3 - 
11 rs6453333 - 5 - 
12 rs12041702 - 1 - 
13 rs17048190 - 2 - 
14 rs2968848 - 7 - 
15 rs16909497 - 10 - 
16 rs10499687 VWC2 7 - 
17 rs17169622 BMPER 7 - 
18 rs41479848 MBIP 14 Involved in LOAD-associated MAPK pathway [180] 
19 rs3007246 - 13 - 
20 rs6429224 RGS7 1 Gene involved in brain signaling [181] 
21 rs10845804 - 12 - 
22 rs12109727 - 5 - 
23 rs12476792 - 2 - 
24 rs6455005 - 6 - 
25 rs11804140 FBXO28 1 - 
 
Table 42 - Top 25 SNPs as ranked by chi squared for ADRC data. 
Rank rsID Gene Chr Comment 
1 rs429358 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
2 rs4420638 APOC 19 In strong linkage disequilibrium with APOE SNPs [156] 
3 rs157582 TOMM40 19 Showed LOAD association in African-American cohort [65] 
4 rs2075650 APOE4 19 Predictive of longevity of LOAD patients [163, 164] 
5 rs7412 APOE 19 APOE risk allele determined by  rs7412 and rs429358 [155] 
6 rs405509 APOE 19 APOE promoter varies LOAD risk [70] 
7 rs8106922 TOMM40 19 Meta-analysis finds significant association with LOAD [69] 
8 rs26845 ECI1 16 - 
9 rs12507679 STAP1 4 - 
10 rs13132585 STAP1 4 - 
11 rs157580 TOMM40 19 Associated with LOAD in Chinese population [71] 
12 rs4496012 - 13 - 
13 rs8082842 RAB31 18 Gene involved in potential treatment [75] 
14 rs9487940 - 6 - 
15 rs34276 ACACB 12 - 
16 rs4865859 - 5 - 
17 rs7985095 - 13 - 
18 rs16976268 - 18 - 
19 rs4796922 - 18 - 
20 rs16841336 PYHIN1 1 - 
21 rs832156 IGFN1 1 - 
22 rs9438881 - 1 - 
23 rs283129 PIN1 5 PIN1 linked to neural apoptosis in LOAD [166, 167] 
24 rs4480661  13 - 
25 rs11985315 TRAPPC9 8 - 
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Table 43 - Top 25 SNPs as ranked by chi squared for CD data. 
Rank rsID Gene Chr Comment 
1 rs2076756 NOD2 16 Associated in independent study [102]  
2 rs10210302 ATG16L1 2 Defects in gene cause susceptibility to IBD, sex-related risk for CD [103] 
3 rs6752107 ATG16L1 2 Defects in gene cause susceptibility to IBD, sex-related risk for CD [103]  
4 rs6431654 ATG16L1 2 Defects in gene cause susceptibility to IBD, sex-related risk for CD [103] 
5 rs3828309 ATG16L1 2 Defects in gene cause susceptibility to IBD, sex-related risk for CD  [103, 104]  
6 rs17234657 - 5 WTCCC finding replicated in independent cohorts [105, 106]  
7 rs2066843 NOD2 16 Associated with CD in independent study [102] 
8 rs3792106 ATG16L1 2 Defects in gene cause susceptibility to IBD, sex-related risk for CD [103, 104] 
9 rs11805303 IL23R 1 IL23 implicated in CD [107]  
10 rs11957215 - 5 - 
11 rs9292777 - 5 WTCCC SNP replicated in independent study [108] 
12 rs10489629 IL23R 1 Replicated in multiple studies [102, 109, 110]  
13 rs17221417 NOD2 16 NOD2 implicated in CD [102] 
14 rs2201841 IL23R 1 SNP implicated in distinct populations [111] 
15 rs4957295 - 5 - 
16 rs10213846 - 5 - 
17 rs6871834 - 5 - 
18 rs4957297 - 5 Replicated independent of WTCCC [112] 
19 rs4957300 - 5 - 
20 rs16869934 - 5 Discovered in BIC analysis of WTCCC [113] 
21 rs12119179 - 1 Associated with a disease with similar genetic profile  [114] 
22 rs11209033 - 1 Cited in patent for testing for autoimmune-associated polymorphisms [115] 
23 rs10512734 - 5 SNP validated in independent study [182] 
24 rs7546245 - 1 In moderate LD with rs11805303 [107] 
25 rs41396545 IL23R 1 Discovered in BIC analysis of WTCCC [113] 
 
 
Table 44 - Top 25 SNPs as ranked by chi squared for HT data. 
Rank rsID Gene Chr Comment 
1 rs4765066 - 12 - 
2 rs488101 - 9 Associated with arterial plaque [116] 
3 rs4867173 - 5 - 
4 rs11782342 KCNB2 8 Discovered as part of epistatic interactions in WTCCC data [86] 
5 rs11024327 OTOG 11 Found in combined analysis of WTCCC data [117] 
6 rs2820037 1 - SNP associated with BP regulation [119] 
7 rs2790622 - 1 - 
8 rs2820038 - 1 - 
9 rs6574988 - 14 - 
10 rs2820046 - 1 - 
11 rs16945811 YWHAE 17 Gene implicated in HT [120] 
12 rs9428826 - 1 - 
13 rs2398162 NR2F2-AS1 15 Population-specific association has been replicated [121] 
14 rs2820026 - 1 - 
15 rs921535 - 15 - 
16 rs10889923 NEGR1 1 - 
17 rs2191003 - 4 - 
18 rs300916 GAB1 4 Discovered in combined WTCCC + Australian cohort [117] 
19 rs1935683 - 6 - 
20 rs13119672 PPARGC1A 4 Gene associated with HT [124] 
21 rs11110912 MYBPC1 12 WTCCC SNP replicated in independent study [119] 
22 rs2840584 SLAMF9 1 - 
23 rs633568 - 11 - 
24 rs1036392 - 2 - 
25 rs973009 ACTN4 4 - 
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